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Sub-Saharan Africa has the highest number of HIV-infected individuals and limited treatment 
programs. The use of Highly Active Antiretroviral Therapy (HAART) has resulted in a 
considerable decrease in morbidity and mortality among HIV-infected individuals. Long-term 
use of HAART has several limitations relating to cost, drug toxicity and adherence. Structured 
Treatment Interruption (STI) has been proposed as a therapeutic approach which limits the 
exposure to continuous HAART, but retains the benefits thereof. The role of HIV-specific T-
cell responses in the control of viraemia has not been well studied in children and it is not 
clear when these responses become detectable or whether they are associated with improved 
viral control. Furthermore, antiretroviral drug resistance is well documented in adults infected 
with HIV-1 clade B virus but comparable information is lacking for chronic paediatric clade C 
virus infection. This pilot study focused on a chronic HIV-infected paediatric cohort from 
Durban, South Africa, to assess the immunologic and virologic responses in perinatal HIV-
infected children undergoing STI.  
 
METHODS 
Thirty chronic HIV-infected treatment naïve children were enrolled and randomised into 
either the treatment interruption or continuous treatment group. Longitudinal measurements of 
viral loads and CD4 percentages were done at scheduled intervals. Peripheral blood 
mononuclear cells (PBMCs) were screened for cytotoxic T-lymphocyte (CTL) gamma 
interferon (IFN-γ) enzyme-linked immunospot (ELISpot) assay  responses using 410 peptides 
which spanned the entire HIV-1 clade C proteome. Intracellular cytokine staining (ICS) was 
done to distinguish between IFN-γ Gag-specific T-helper and cytotoxic T cell responses. Pre-
HAART drug resistance mutations testing and HLA typing were done for all children.  
 
RESULTS 
There was a significant increase in the median CD4 percentage after HAART was introduced. 
Six children randomized to the STI arm did not undergo treatment interruption because their 
viral loads remained detectable at the time of scheduled interruption. Most HIV proteins were 
 xix
targeted in this paediatric cohort. Gag was the most frequently targeted HIV-1 protein 
(93.1%). In both treatment groups, there were broadening of T-cell responses, however, the 
magnitude of T-cell responses decreased over time on HAART. Drug-resistant mutations were 
detectable in 4/29 children before initiation of HAART.  
 
CONCLUSION 
In this pilot study, the HIV-1-specific CD8+ and CD4+ T-cell responses were detected before 
and during HAART. Although the treatment interruption period was short, there were no 
adverse outcomes in either the continuous or treatment interruption groups in terms of death 
or other clinical outcomes. This study suggests that it is important to continue to explore 











“In all human affairs . . . there is a single dominant factor – ‘TIME’. To make sense of the 
present state of science, we need to know how it got like that: we cannot avoid an historical 
account . . . .  To extrapolate into the future we must look backwards a little into the past”   -- 
JM. Ziman  
 
The human immunodeficiency virus (HIV) has generated two and a half decades of research 
in trying to understand how this pathogen interacts with its human host, leading to infection 
and disease outcomes. Although important concepts such as the complex interaction between 
human leukocyte antigen (HLA) types and the virus to modulate immune responses have 
emerged; as well as major technological advances that have allowed the study of T-cell 
dynamics, there still remain many unanswered questions (Rowland-Jones et al, 2003). Despite 
many accompanying conflicting debates and conflicts, more than two decades of HIV research 
has helped us better understand this infection and how to prevent and treat it. However, no 
vaccine has yet been shown to either prevent infection or control viral replication i.e. 
preventative or prophylactic vaccine. 
 
 
1.1 EPIDEMIOLOGY OF HIV GLOBALLY, REGIONALLY AND 
SOUTH AFRICA 
 
More than twenty five years have passed since HIV was discovered and shown to be the cause 
of AIDS. However, the disease burden of the HIV/AIDS pandemic and the consequent human 
suffering continue to grow steadily (Garber et al, 2004).  
 
HIV is the leading cause of death worldwide especially among those in the 15-59 year age 
group (UNAIDS/WHO Worldwide HIV and AIDS Summary, 2007). It is considered a threat 
to the economic well-being, social and political stability of many nations (UN Population 
Division, 2005 and UNAIDS, 2006). Globally, the number of people living with HIV rose 
 2 
from around 8 million in 1990 to almost 33 million in 2007. Statistical reports have indicated 
a decrease in the estimated number of people living with HIV from 39 million in 2005 to 33 
million in 2007. It was estimated that 2.1 million HIV-infected persons died in 2007 of which 
1.7 million were adults and 0.33 million were child deaths worldwide (Kaiser Family 
Foundation: HIV/AIDS Policy Fact Sheet, 2007). 
 
Regional statistics at the end of 2007 indicated that sub-Saharan Africa has 22.5 million adults 
and children living with HIV/AIDS. New HIV infections in adults and children were 1.7 
million and 1.6 million deaths were reported in adults and children. More than 11 million 
children in Africa have been orphaned by AIDS. The estimated number of people living with 
HIV in sub-Saharan Africa was 69% in 2007 (Kaiser Family Foundation: HIV/AIDS Policy 
Fact Sheet, 2007). 
  
These alarming figures have highlighted sub-Saharan Africa as the hardest hit region in the 
world with the highest number of individuals infected with HIV-1. At least 22.5 million 
people (adults and children) in sub-Saharan Africa are infected with HIV with an adult 
prevalence of 5% thus making HIV/AIDS the leading cause of death in sub-Saharan Africa.                                                                     
 
                    
Figure 1.  The number of people living with HIV in the world (shown in brown bars) in 
contrast to the number of people living with HIV in Sub-Saharan Africa (shown in 
orange bars).  
Adapted from: Worldwide AIDS and HIV Statistics including Deaths, 2007 
[www.advert.org/worldstats.htm    (Accessed 12 June 2007)] 
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South Africa is experiencing one of the most severe AIDS epidemics in the world. By the end 
of 2005, it was estimated that almost 1000 deaths occurred every day. AIDS deaths have 
become alarmingly common in South Africa and almost 71% of all deaths are among those 
aged 15-49 years (UNAIDS, 2007). The South African Department of Health Study estimated 
that 29.1% of pregnant women were living with HIV in 2006. KwaZulu Natal recorded the 
highest rates (39.1% prevalence in 2006) followed by Mpumalanga and Free State (32.1% and 
31.1% respectively). The most rapid increase in South Africa’s HIV prevalence occurred from 
1993-2000, during which time the country was distracted by major political changes. There 
has been much progress, with the introduction of South African National HIV Treatment 
Programme and antiretroviral treatment started in 2004, although the distribution of drugs has 
been relatively slow. 
 
It is unfortunate that this region had to bear the brunt of more than five hundred thousand 
infants who became HIV infected prior to the introduction of the mother-to-child prevention 
programs. In addition, due to civil conflicts and wars, large numbers of refugees are produced 
and they are at greater risk of contracting the disease (Girard et al, 2006). The estimated 
population for South Africa was 47.4 million at mid-year 2006, with 15.3 million children 
between the ages of 0-14 years. KwaZulu-Natal (KZN) has the largest share of the South 
African population, with just over 20% of the total population living in the province (SA 
News, 2006).  
 
The estimated HIV prevalence among antenatal clinic attendees for KZN was 33.5% in 2001, 
which increased to 39.1% in 2006 with the highest estimation of 40.7% in 2004. This increase 
occurred despite the South African High Court who ordered the Government to make the drug 
nevirapine available to pregnant women to help prevent the transmission of HIV to their 
unborn babies (HIV and AIDS Stats, 2005). 
 
In 2005 it was estimated that at least 2 million children in Sub-Saharan Africa were living 
with HIV. They represented more than 85% of all children living with HIV worldwide 
(UNAIDS, 2006). The majority of these children would have become infected with HIV 
during pregnancy or through breastfeeding from their mothers who are HIV infected. In many 
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developed countries, steps were taken to virtually eliminate Mother To Child Transmission 
(MTCT). Sub-Saharan Africa continues to be severely affected by this problem and this is due 
to the lack of drugs, services, information and shortage of testing facilities. 
 
HIV infections are alarmingly common among children in South Africa especially because 
women who are HIV positive are still not receiving antiretroviral treatment that could prevent 
HIV transmission to their unborn babies. Government antenatal surveys indicated that there 
were 260 000 children below the age of fifteen years, living with HIV in 2006 (Department of 
Health, 2006).  Children living with HIV are highly vulnerable to illness and death unless they 
are provided with paediatric antiretroviral treatment. Unfortunately there is a great shortage of 
antiretroviral treatment in South Africa. The AIDS Law Project in Gauteng, estimated that 50 
000 children in South Africa were in need of antiretroviral treatment at the beginning of 2006 
but only 10 000 were receiving them (Mail and Guardian Online, 2006). These statistics 
underline the urgency for the development of an HIV vaccine, in one of the populations most 
severely affected. 
 
Despite the introduction of the PMTCT programs and the start of the South African 
Government's treatment programs, the high levels of new infections occurring in South Africa 
reflects the difficulties that are being faced by the AIDS education and prevention campaigns. 
In addition, the high number of deaths in the country reflects the continuing lack of 
antiretroviral treatment availability. South Africa has had a turbulent past and there are many 
possible reasons why South Africa has been so badly affected by AIDS, these include poverty, 
social instability, lack of government action, stigma and discrimination, prohibitive cost of 
antiretroviral drugs, delivery delays, insufficient counseling of HIV infected individuals and 









1.2.1  HIV structure 
 
Like all viruses, HIV cannot grow or reproduce on its own. It must infect the cells of a living 
organism in order to make new copies of itself. Outside the human cell, it exists roughly as 
spherical particles (called virions) and these particles are too small to be seen through an 
ordinary microscope but they can be seen clearly with an electron microscope. 
 
                                                    
                                                                                                                                                         
                     
 
 
Figure 2.  Cross-sectional schematic diagram of HIV virion 
Adapted from:  http://tutor.lscf.ucsb.edu/instdev/sears/immunology/chapter19/figure19-08a 
(Accessed 18 April 2007) 
 
The virion surrounds itself with a coat of fatty material known as the viral envelope. From this 
membrane, there are 72 glycoprotein (gp) projections composed of the proteins gp41 and 
gp120. Gp41 is a transmembrane molecule that crosses the lipid bi-layer of the viral envelope. 
Gp120 is non-covalently associated with gp41 and it serves as the viral receptor for the CD4 
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host cells. The matrix is the region found just below the viral envelope and this is composed 
of the protein p17. The conical shaped viral core (capsid) comprises of the p24 protein and is 
located below the p17 region. There are three enzymes found inside the viral core, which are 




1.2.2  HIV genome  
    
                                                                                                                                                                              
 
        
 
Figure 3.  The HIV genome with proteins specific to HIV 
Adapted from:  www.yale.edu/bio243/HIV/newhiv.html 
(Accessed 17 April 2007) 
 
 
HIV’s genetic material consists of two identical strands of RNA which are found within the 
core of the virion. HIV has nine genes, three of which contain the information needed to make 
structural proteins for new virus particles. These are the gag (group specific antigen gene), pol 
(polymerase gene) and the env (envelope gene). The other six genes code for the proteins that 
control the ability of HIV to infect a cell, produce new copies of the virus or to cause disease. 
These genes are known as tat (encodes transactivator protein), rev (encodes a regulator of 
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expression of viral protein), vif (associated with viral infectivity), vpu (viral protein U), vpr 
(viral protein R) and nef (encodes negative regulator protein). 
 
1.2.3 The origins and diversity of HIV 
 
Although the origins of HIV are unclear, Robert Gallo and Luc Montagnier discovered the 
HIV-1 virus around 1983-1984 and believed that it was the viral cause of a new disease 
(Cichocki, 2007). HIV-1 is predominant worldwide and mutates very easily. There are 
different strains of HIV-1 and they are categorized in groups and subtypes called clades.  
 
The origins of HIV and AIDS have captured the attention of many scientists ever since the 
disease first came to light in the early 1980s. The first recognizable cases of AIDS occurred in 
the USA (New York and San Francisco) where a number of homosexual men suddenly 
developed rare opportunistic infections (Gottlieb et al, 1981). However, these infections were 
resistant to the normal treatment. It then became obvious that these men were suffering from a 
common syndrome, which occurred in a setting of markedly reduced circulating CD4+ T-cells. 
The suspicion that AIDS has an infectious cause was confirmed in 1983-1984, when the 
isolation of a retrovirus from the blood of patients with AIDS was reported (Barre-Sinnoussi 
et al, 1983). Barre-Sinnoussi and Montagnier had obtained several isolates of the human 
retrovirus and it was their findings that led to the award of The Nobel Prize in Physiology or 
Medicine in 2008 for the discovery of the “Human Immnodeficiency Virus” (The Nobel Prize 
in Physiology or Medicine, 2008). These findings allowed for the development of a reliable 
test for HIV infection: looking for the presence of circulating immunoglobulin-g antibodies 
specific for HIV which provided the basis for screening of donated blood and for large-scale 
epidemiological studies (Levy et al, 1984). 
 
HIV is a lentivirus. Like all viruses of this type, it attacks the immune system. Lentiviruses are 
part of a larger group of viruses known as retroviruses. The name “lentivirus” means “slow 
virus” because these viruses take a long time to produce any noticeable adverse effects in the 
body. They have been found in a number of different animals, which includes cats, sheep, 
horses and cattle. It is generally believed that HIV-1 is a descendant of the simian 
immunodeficiency virus (SIV), which is a lentivirus that affects monkeys. One of the earliest 
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documented cases of HIV-1 infection was identified in a stored plasma sample collected from 
an adult male in 1959 living in what is now the Democratic Republic of Congo (Barre-
Sinoussi et al, 1983). Analysis of this sample in 1998 suggested that HIV-1 was introduced 
into humans around 1931 (Korber et al, 2000).  
 
1.2.4  The natural course of HIV-1 infection 
 
The progression of the HIV infection may be measured through various outcome measures 
such as  the rate of decline in the CD4+ T-cell count, increase in plasma viral load and the HIV 
associated opportunistic infections (Paranjape, 2005). 
                     
 
Figure 4.  The natural course of HIV-infection.  
The course of infection can be categorized into three phases namely: the acute phase, the 
asymptomatic phase and the AIDS phase  
Adapted from:  www.journaids.org/hivaidsoverview       (accessed 12 June 2007) 
 
 
1.2.4.1 The acute phase 
Early events during acute HIV-1 infection are critical in determining the course of disease 
progression. Since there are no HIV-1 specific antibodies detectable during this early phase, 
diagnosis of acute HIV-1 infection is often missed in the majority of cases as other viral 
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infections are assumed to be the cause of symptoms (Altfeld and Walker, 2001). Antibodies to 
HIV p24 antigen begin to appear within several weeks of acute infection. The p24 antigen 
levels once present persist and then increase during active viral replication (Quin, 1994). The 
principle impact of HIV infection on the immune system is the destruction of the CD4+ T-
lymphocytes. Patients with an initial diagnosis of HIV-infection should have CD4+ T cell 
measurements performed approximately every six months to see if a declining trend is noted 
(Gupta et al, 2004).  
 
During HIV-1 infection, anti-viral CTL responses develop and persist. Unfortunately, CTL 
escape mutations are selected, thus helping the virus evade immune surveillance (Allen et al, 
2000 and Goulder et al, 2001). The virus replicates extensively during the acute phase of 
infection with viral titers reaching extraordinary levels (Little et al, 1999). However, these 
high levels are short-lived thus indicating that the immune system can generate immune 
responses that could control the replication of the virus. Viremia declines before reaching a 
set-point (Altfeld and Walker, 2001). 
 
 
1.2.4.2 Asymptomatic phase 
The asymptomatic phase of HIV infection (chronic HIV infection) is where the viral load 
reaches a viral set point and the HIV antibody level tends to plateau at high levels,  however 
the CD4 cell count is the hallmark of HIV infection and the rate of loss in each person is 
unique (Gupta et al, 2004). 
 
 
1.2.4.3 AIDS phase 
The AIDS defining stage of HIV-1 infection has a rapid decline in the CD4 cell count with an 
increase in viral load if an escape mutant is present. This occurs in conjunction with other 
opportunistic infections as the immune system has weakened tremendously. Early processes 
that try to contain the pathogen during the interim period when adaptive immune responses 
are not yet ready are known as innate immune responses. The innate immune responses may 
play a major role in initial containment of infection and hence may be crucial in the acute HIV 
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infection phase. Almost all HIV infected individuals mount HIV-specific immune responses. 
However, only few can control the viremia successfully for prolonged periods (Paranjape, 
2005). 
 
The immune system is a complex network of cells and chemicals and its mission is to protect 
us against foreign organisms and substances. During HIV-1 infection, anti-viral CTL 
(Cytotoxic T lymphocyte) responses develop and persist. CTL escape mutants are selected and 
this helps the virus to evade immune surveillance (Mahnke et al, 2006). 
 
 
1.2.5 Clinical Staging of HIV/AIDS 
 
HIV disease staging and classification systems are critical tools for tracking and monitoring 
the HIV epidemic which provides important information to clinicians for clinical 
management. The CDC and WHO are the two major classification systems that is currently in 
use. The clinical staging and case definition of HIV for resource settings were developed by 
the WHO in 1990 and was revised in 2007 (World Health Organization, 2007). The 
immunologic criteria for diagnosing advanced HIV in adults and children five years or older 
with confirmed HIV infection is having a “CD4 count less than 350 per mm3 of blood in an 
HIV infected adult or child” and for children younger than five years of age is: 
a) CD4 percent less than 30 among those younger than 12 months 
b) CD4 percent less than 25 among those aged 12- 35 months and 
c) CD4 percent less than 20 among those aged 36-59 months 
 
 
1.2.6  Natural immune control 
 
Individuals who have been infected with HIV for more than 20 years and maintain viral loads 
below the detection levels or at low levels, without the need of antiretroviral drug therapy, 
clearly suggest that immune control of HIV is indeed possible. Viral and genetic factors 
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together with the host immune responses contribute significantly to the delay in HIV-1 disease 
progression in HIV-1 infected long-term nonprogressors (LTNPs) (Baoz et al, 2002).  
 
Studies of many chronic viral infections in which containment rather that eradication is the 
outcome suggests that the quality of the immune system plays a central role in viral control. 
Some LTNPs appear to have strong cytotoxic T-lymphocyte (CTL) responses as well as T-
helper responses directed against HIV (Altfeld et al, 2001).  
 
It is evident that human leukocyte antigen (HLA) class I genes are associated with the ability 
to mediate strong immune pressure against HIV-1 (Elrefaei et al, 2004; Garber et al, 2004 and 
Altfeld et al, 2001). Specific HLA alleles have been associated with slow (eg. HLA-B*57 and 
B*27) or rapid (HLA-B*35) disease progression (Garber et al, 2004 and Altfeld et al, 2001). 
It is presumed that the diversity and specificity of HIV-1 epitopes presented by protective 
HLA alleles result in enhanced recognition and viral control by CTLs. 
 
 
1.2.7  Natural killer cell response to HIV  
 
In most viral infections, cell-mediated immune responses play a pivotal role in arresting 
and/or eliminating the infecting agent (Miller, 2002) with the outcome of many of these viral 
infections being containment rather that eradication (Altfeld and Rosenberg, 2000). This 
includes cytotoxic responses of Natural Killer (NK) cells as well as CD4+ and CD8+ T-cells.  
 
Natural Killer cells are bone marrow derived and do not require thymic processing. They kill 
other cells within approximately four hours of exposure. Cytotoxic T-cells differ from NK 
cells as they require exposure to antigens. In HIV-1 infection, NK cells are able to recognize 
virus infected cells and mount an antibody-dependent cell-mediated cytotoxity (ADCC) 





1.2.8  Immune Pathology 
 
1.2.8.1 CD4+ T-cell response 
The negative correlation of strong HIV-1 specific CD4+ T helper cell responses and viral load 
indicates that CD4+ T helper cells may also play an important role in the immune response to 
HIV-1 (Rosenberg et al, 1997). 
 
Virus-specific CD4+ helper-cells (Th) play an important role in the induction and maintenance 
of effective CD8+ T-cell function in adults (Altfeld et al, 2001; Wilson 2006 and Kuhn et al, 
2001). CD4+ helper-cells also play an important role in early immune response to HIV, but 
HIV infection leads to the progressive loss of CD4+ T-cells and their function, more 
specifically CD4+ T-cells have been shown to be preferentially depleted in the gut (Lim et al, 
1993) early after infection (Lacabaratz-Porret et al, 2004; Altfeld et al, 2001). Studies in 
adults have shown that HIV-specific CD4+ T–cell responses may be detected during early 
infection (Lacabaratz-Porret et al, 2004), but they are lacking during chronic infection, except 
in cases of long-term non-progressors (Lacabaratz-Porret et al, 2004 and Jansen et al, 2006).  
 
A study performed on acutely HIV-1 infected adults (Altfeld et al, 2001) has shown that the 
CTL responses are weak and these findings were consistent with the cross-sectional data from 
another study (Dalod et al, 1999) where the breadth of responses were less extensively 
characterized. Individuals who are treated in early HIV-1 infection may benefit from strategies 
which are aimed at enhancing virus-specific CTL responses, whereas individuals who are 
treated later in HIV-1 infection may benefit from the strategies aimed at enhancing HIV-1 
specific T-helper cell functions so as to broaden the CTL responses which will help combat 
the viral diversity (Altfeld et al, 2001).  
 
Effective immune control in animal models of chronic viral infections is associated with an 
adaptive immune response that includes CD4+ and CD8+ T-cell responses (Ramduth et al, 
2005). Antiretroviral therapy in chronic HIV-1 infection has resulted in increased CD4+ cell 
counts but it has not resulted in the restoration of strong or persistent virus-specific CD4+ T-
cell proliferative responses (Rosenberg et al, 1997). 
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1.2.8.2 CD8+ T-cell response 
 
In studies like the murine lymphocytic choriomeningitis virus model, there is indication that 
maintenance of effective CTLs does require the presence of virus-specific T-helper cells 
(Matloubian et al, 1994). The inverse association between virus-specific CD4+ cell responses 
and viral load and the association between strong HIV-1 specific CTL and T-helper cell 
responses clearly suggest that CD4+ T-cells are required for the maintenance of effective CTL 
response in HIV-1 infected individuals (Rosenberg et al, 1997; Kalams et al, 1999). 
 
CD8+ T-cells contribute to the partial immune control of HIV-1 in acute, chronic and the long-
term non-progressing infection (Borrow et al, 1994 and Koup et al, 1994). The anti-viral 
effect of these CD8+ T-cells is mediated by effector mechanisms, which include the release of 
lytic granules and the release of cytokines and chemokines (Harty et al, 2000). The HIV-
specific CD8+ T-cells play a major role by suppressing HIV replication. The diversity and 
specificity of these HIV-specific CD8+ T-cells are important for the efficiency of the immune 
response as well as control of the virus that bears immune escape mutations (Buseyne et al, 
2006).  
 
Data from animal models have shown that the depletion of CD8+ T-cells is associated with an 
increase in viral load (Matloubian et al, 1994) and the inverse correlation between the HIV-
specific CTLs and viral loads was seen in untreated HIV-1 chronic infection (Ogg et al, 1998). 
Most HIV-1 infected individuals who have poor control of viremia, progress to AIDS without 
antiretroviral therapy despite the antiviral activity of the CTLs in control of viremia (Altfeld et 
al, 2001). 
 
Studies show that there are differences in the CD8+ T-cell repertoire of responses to the whole 
HIV-1 genome from adult patients during the acute and chronic phase of HIV-1 infection 
(Goulder et al, 2001 and Alter et al, 2007). 
 
Immunohistochemical studies on mucosal immune cells in the gut of adults have shown that 
the CD4+ lymphocyte subset is depleted and the CD8+ lymphocyte subset is expanded in 
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AIDS subjects (Rodgers et al, 1986; Budhraja et al, 1987; Jarry et al, 1990). The increase in 
mucosal CD8+ lymphocytes appears to parallel the expanded blood CD8+ populations as a 
result of HIV infection. The importance of CD8+ T-cells in host protection has been 
increasingly recognized and the loss of CD4+ T-cells in HIV implies an increased role for 
CD8+ T-cells in host defense (Scott et al, 1991). 
 
The initial HIV-specific CD8+ T-cell response in acute adult HIV-1 infection is of low 
magnitude and is narrowly directed against a limited number or epitopes. However, these 
responses broaden during the prolonged antigen stimulation in the chronic phase of the HIV-1 
infection (Altfeld et al, 2001; Dalod et al, 1999; Oxenius et al, 2000). Viral replication tends 
to wane during the later stages of HIV-1 infection, although the HIV-specific CD8+ T-cell 
responses are generally broader and there is a vigorous immune response in the chronic phase 
of infection. These findings have suggested that the quality and specificity of the initial CD8+ 
T-cell responses may be associated with initial control of the viral replication as apposed to 
the magnitude of the responses (Pantaleo et al, 2004). 
 
 Some studies have shown that in chronic HIV-1 infection, the CD8+ T-cell responses are 
directed against HIV-1 Gag in subjects with low viral loads and slow disease progression 
(Addo et al, 2003; Gray et al, 1999; Kiepiela et al, 2007). CD8+ T-cells cannot adequately 
suppress HIV-1 infection by themselves which leads to subsequent impairment of the CD8+ T-
cells (Migueles et al, 2002; Lichterfeld et al, 2004). Evidence in studies with animal models 
and HIV-1 clade B infection in humans indicate that long-term maintenance of effective 
cytotoxic T lymphocyte activity is dependent on the functionality of the CD4+ T-cells (Kalams 
et al, 1999; Cao et al, 2003). The preferential targeting of HIV-1 Gag responses indicates the 








1.3 Pediatric HIV infection and treatment  
 
Acquired immunodeficiency syndrome is now believed to be the leading cause of death in 
sub-Saharan Africa and the fourth biggest killer in the world (UNAIDS/WHO Worldwide 
HIV and AIDS Summary, 2007).  Most HIV-1 infected subjects live in Africa, and women of 
child-bearing age are disproportionately affected.  
 
The HIV epidemic has grave implications for children, particularly in Africa where HIV 
prevalence is high (Chakraborty et al, 2005). In adults, the clinical manifestations of HIV-1 
infection and the course of immunologic and virologic markers differ from that of children. 
Most children acquire HIV-1 infection perinatally and their immune systems are immature at 
the time of infection and are exposed to high-levels of viral replication. 
 
In developed countries, studies have shown that children infected with HIV-1 perinatally, 
progress rapidly to AIDS (within a year), before the introduction of HAART. The median 
time to reach the AIDS stage is ~7 years and a minority of children remain clinically 
asymptomatic beyond their childhood and some even into adolescence (Goulder et al, 2001). 
 
Earlier studies on HIV-1 specific CTL responses among perinatally infected children indicated 
that these CTL responses emerged later in the course of HIV-1 infection and were much 
weaker than the responses that are seen in adults (Feeney et al, 2003b; Buseyne et al, 1993; 
Buseyne et al, 1998a and Luzuriaga et al, 1995). However, these studies relied on techniques 
that were less sensitive than some techniques used currently. Recent studies have shown that 
CTL responses can be detected very early in infants (Lohman et al, 2005 and Thobakgale et 
al, 2007). However, these responses are not clearly associated with clinical outcomes and the 
finding that the older infants had stronger CTL responses which may be due to age-related 
maturation (Lohman et al, 2005).   
 
Little is known about the magnitude and breadth of paediatric HIV-1 specific CTL responses 
beyond infancy and early childhood. In the USA, a large proportion of HIV-1 infected 
children are now entering the second or third decade of life. This is mainly due to the 
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changing demographics of paediatric HIV-1 in developed countries (Feeney et al, 2003a). 
Antiretroviral interventions to reduce Mother-To-Child-Transmission (MTCT) and HAART 
therapy have played a major role in reducing the HIV-1 transmission rates in developed 
countries.  
 
Although substantial improvement had been made with adults being treated with ARVs in 
sub-Saharan Africa, progress for children has lagged behind (Sutcliff et al, 2008). The South 
African National HAART programs which began in 2004 have proven to be effective but 
delays in HAART initiation are experienced. New guidelines for the PMTCT programs   were 
launched in South Africa in February 2008 (Alcorn, 2008). However, in many of the 
provincial hospitals this implementation was expected to begin in June 2008. It is delays like 
these that increase the number of new infections and the number of subjects waiting to be 
treated with HAART. 
 
Only a small proportion of HIV-1 infected children are now entering or have already entered 
the second decade of their lives. Most of these children have already started antiretroviral 
therapy. Data regarding the HIV-1 specific immune responses in these perinatally infected 
children whose immune systems have matured in the presence of HIV-1 is limited. The 
relationships between the frequency of HIV-specific T-cells, treatment strategies and viral 
replication have been well established in adult HIV-1 infection but are less well established in 
older chronic HIV-1 infected children (Buseyne et al, 2005). 
 
1.3.1 HAART in children 
 
Highly Active Anti-retroviral Therapy (HAART) has significantly improved HIV-associated 
morbidity and mortality (Boschi et al, 2004). Although HAART does not eradicate HIV from 
the infected individual, there are various strategies, which have been proposed to facilitate the 
management of individuals on therapy. HAART has however revolutionized the treatment of 
HIV, but has its drawbacks in the manifestation of side effects and becomes ineffective when 
the virus develops resistance.  
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The global impact of the HIV epidemic on children worldwide has been devastating. Statistics 
have shown that South Africa is one of nine countries where the mortality of children less than 
5 years of age is increasing at an estimated annual rate of 1,6% (UNAIDS, 2007) and in the last 
decade has orphaned far too many children. South Africa has one of the highest antenatal HIV 
prevalence rates in the world where most of the infections in children result from perinatal 
transmission. PMTCT, one of the largest antiretroviral treatment programmes has mitigated 
this problem. This intervention programme is currently an effective strategy for reducing the 
size of the paediatric HIV epidemic (Coetzee et al, 2005; Rollins et al, 2007).  
 
The use of HAART has resulted in a considerable decrease in morbidity and mortality among 
HIV-1 infected adults and children worldwide. To replicate these successes in less developed 
countries where HIV-1 is endemic has certainly proved to be a challenge not only for 
governments but nongovernmental organizations and agencies (Chakraborty et al, 2003). The 
World Health Organisation (WHO) estimated that only 3% to 4% of HIV- infected children in 
Africa who require immediate treatment are actually receiving it (UNAIDS, 2007). 
 
HAART by itself cannot eradicate HIV from the infected infant or child, but it can certainly 
improve the quality and prolong lives. HIV infected children on HAART reconstitute their 
immune system similar to adults. However, children have a more rapid increase in naïve CD4+ 
T-cells and normalize their CD8+ T-cell repertoire  better than adults and this is due to the 
increased function of their thymus (Hazra et al, 2005) ). Without antiretroviral treatment in 
Africa, the mortality rate of HIV-infected children 2 years of age was estimated to be 60% and 
75% in children before the age of 5 (Nicoll et al, 1994 and Spira et al, 1999).  
 
Without HAART the development of AIDS in HIV-infected infants and children occurs more 
rapidly and this is due to their immature immune system, which poorly suppresses HIV. In 
contrast to adults, AIDS typically averages 10-12 years from the time of infection to the 
development of AIDS (Reute, 2006). The initiation of antiretroviral therapy is preceded by the 
clinical staging of the HIV-infected individual, however immunological staging for children is 
important. CD4 testing is important but not essential by itself for the initiation of HAART in 
children and therefore should be used in conjunction with their clinical staging. The 
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measurement of CD4 percentage is recommended in infants and young children because the 
CD4 absolute count is associated with specific levels of immuno-suppression and this tends to 
change with age.  
 
A step-by step guide which is dependent on age has been established for the management of 
HIV-infected children on antiretroviral therapy.  All children <1 year with clinic WHO 
staging 2, 3 and 4 or who have a CD4% of ≤ 35 or an absolute CD4 cell count <1500 cells/ 
mm3 should start antiretroviral therapy. Children between the ages of 1-5 years with clinic 
WHO stage 3 and 4 or who have a CD4 count ≤ 20% as well as children older than 5 years 
with a clinical WHO stage 3 and 4 or a CD4 count of <15% or who have an absolute CD4 
count of <200 cells/ mm3 should be treated with antiretroviral therapy. Co-trimoxazole 
prophylaxis is given to HIV-infected children if they have a CD4 count of < 25% – 35% 
depending on their age and in HIV exposed children < 12 months until the HIV is excluded. 
 
In the absence of antiretroviral therapy, HIV-infected children die before their fifth birthday 
(Newell et al, 2004) and vertically HIV-infected infants progress to AIDS or death in the first 
year of life (Gray et al, 2001). Although only 2/20 HIV-1 infected infants had viral loads less 
than 10, 000 copies/ml and a CD4% of > 30, by the age of 2 years without antiretroviral 
therapy, 85% of HIV-1 infected infants on the Paediatric Early HAART And Structured-
Interruption Study (PEHSS), in KwaZulu-Natal, met with the current WHO criteria to initiate 
HAART within 12 months of infection (Thobakgale et al, 2007).  
 
HAART used alone, despite the benefits, has proved to be insufficient to completely eradicate 
viral reservoirs. Under current guidelines, HAART has to be administered throughout life. 
However, drug-induced toxicities and issues relating to treatment adherence as well as the cost 
of providing continuous HAART to a large number of HIV-1 infected individuals has proven 
difficult for most developing countries. Some HIV-infected individuals refuse treatment and 





1.3.2 HIV-1 specific CD4+ and CD8+ T-cell responses   
 
A study that focused on acute HIV-1 infected infants, reported that HIV-1 specific CD4+ T-
cell responses were detected in a 6 day old untreated infant suggesting that in-utero priming of 
CD4+ T cells against HIV-1 does occur (Ramduth et al, 2008). This study also indicated that 
there was a greater CD4+ T-cell proliferative response seen in infants who had undergone 
antiretroviral treatment as apposed to the untreated infants, where the CD4+ T-cell responses 
were virtually absent.  
 
The longitudinal assessment of HIV-specific T-cell responses in HIV-1 acute paediatric 
infection is currently being undertaken. Preliminary data indicates that Gag-specific CD4+ T-
cell responses in acutely HIV-1 infected infants are weak or undetectable in the first six 
months of life (Thobakgale et al, 2007). 
 
Many studies have examined the CD4+ T-cell responses in both the acute HIV-1 infected 
(Chakaraborty et al, 2005; Luzuriaga et al, 2000) and chronic (Feeney et al, 2003b; Feeney et 
al, 2004) HIV-1 infected infants and children. However, in chronic HIV-1 paediatric 
infection, the assessment of CTL responses in children undergoing STIs, is yet to be 
determined. 
 
Although Buseyne et al, (1998b) and Sandberg et al, (2003) demonstrated that HIV-specific 
CD8+ T-cell responses can be detected in children before the age of  6 months, Thobakgale et 
al, (2007) proved that these HIV-specific CD8+ T-cell responses can be detected in infants 
from the first days of life. However these responses from the paediactric studies indicated that 
they were weaker than in adults (Buseyne et al, 1998b; Sandberg et al, 2003).  
 
Studies with paediatric subjects showed that they mount a very weak and narrow CD8+ T-cell 
response to HIV-1 Nef epitopes as compared with adult subjects (Chandwani et al, 2004; 
Buseyne et al, 2006). The frequency of detectable CD8+ T-cell responses in children was low. 
Using the ELISPOT assay, the magnitude of these responses was documented to be low 
(Buseyne et al, 2006). 
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Data from a study has shown that HIV-1 specific CD8+ responses in late childhood are similar 
in both the magnitude and breadth to those in adults (Feeney et al, 2003b). In perinatal HIV-1 
infection, the immune system of the newborn is immature at the time of primary infection and 
is therefore exposed to prolonged high-levels of viral replication. There is decreased IFN-γ 
production by the CD8+ T-cells in young children and this may lead to the impairment of their 
antigen-presenting cells (Adkins et al, 2004; Marshall-Clarke et al, 2000; Rouzioux et al, 
1997). Studies have shown that low HIV-specific IFN-γ producing CD8+ T-cell responses 
persist in children 6 months of age (Scott et al, 2001) to children 4 years of age (Sandberg et 
al, 2003). 
 
 The frequency of HIV-specific IFN-γ producing CD8+ T-cells has been shown to be 
dependent on age and unrelated to plasma viral loads or CD4 and CD8 T-cell levels in 
children not receiving HAART as compared to children receiving HAART, where the plasma 
viral load is an important determinant in the frequency of HIV-specific IFN-γ producing CD8+ 
T-cells (Buseyne et al, 2005). 
 
 
1.4 Review on Structured treatment interruptions    
 
The long-term use of HAART in patients is not only expensive but difficult for patients to 
follow as the long-term use generates drug toxicity. Therapeutic approaches, which seek to 
limit the exposure to ARVs, but retain the benefits of continuous therapy, have highlighted the 
area of investigation of Structured treatment interruptions (STI) (Azzoni et al, 2003). 
 
STI has been suggested as a possible alternative to continuous therapy. STI involves the 
alternating “on-and-off” cycles of HAART in order to enhance the use of HAART (Lisziewicz 
et al, 2002). Figure 5 is an illustration of the immunological rationale for STI in controlling 
the virus using HAART.  It has been hypothesized that a brief and slow increase in HIV 
viremia, which results from the suspension of HAART, might boost the HIV-specific CD8+ 
and CD4+ T-cells (Altfeld and Walker, 2001).  With subsequent structured treatment 
(indicated by the shaded regions), in figure 5, the viral levels have decreased to low levels and 
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the CTL and T-helper responses have increased over time. This is an indication that the CTL 
and T-helper responses have control over the viral replication. 
 
 After the subsequent suppression of the virus with the re-introduction of HAART, the CD8+ 
T-cells might be able to have better control of the virus. If the use of STIs leads to 
strengthening of the immune system, this would alleviate ARV therapy hence there would be 
no side-effects and less chance of the development of resistance.  
              
    
 
                     
 
Figure 5.  Illustrates the possibility of STIs in HIV-1 acute infection that would lead to 
immune boosting and subsequent control of viremia without the use of drugs 
Adapted from: Marcus Altfeld, 2001   
 
There have been several studies that have assessed the clinical, immunologic and virologic 
outcomes following STIs in adults treated with HAART during chronic infection (Altfeld et 
al, 2001). Viral levels were shown to have approximated pre-treatment levels (Ruiz et al, 
2000; Hatano et al, 2000) and HIV-1 specific CD4+ and CD8+ T-cells responses were 
enhanced (Papasavvas et al, 2000).  
 
A loss of CD4 T-lymphocytes and a rapid viral rebound is usually experienced in patients who 
discontinue HAART (Papasavvas et al, 2000). Subsequent studies have shown that STIs in 
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adults acutely infected with HIV induce HIV-specific responses mediated by the CD4+ and 
CD8+ T-cells, which may enhance control of viremia (McFarland et al, 2003). The “Berlin 
patient” was probably the first recognized example of the STI concept. He received 
antiretroviral therapy before complete seroconversion, indicated by Western Blot and had 
stopped ARV therapy two weeks after starting and then resumed therapy a week later after his 
viral load had rebounded from < 500 copies/ml to 8000 copies/ml. He resumed ARV therapy 
for a period of three months and then stopped ARV therapy and his viral load remained 
undetectable for more than two years. The presence of increased levels of HIV-specific CD4+ 
T-cell responses in the “Berlin patient” led researchers to speculate that the treatment 
interruption cycles had allowed for the viral antigen to be re-exposed and thus stimulated the 
HIV-specific cellular immune responses (Ball, 2003). 
 
Studies have shown that a minority of chronic HIV-1 infected individuals are able to suppress 
the virus after STIs without HAART. However, rapid declines were observed in the CD4+ T-
cell counts with an inversely proportional viral load during STIs (Youle et al, 2000). An STI 
regime of HAART appears to be most beneficial during the acute phase of HIV-1 infection 
because of the development of enhanced HIV-1 specific cellular immune responses, which 
could alter the viral set point (Oxenius et al, 2002). Results have been encouraging thus far for 
patients on HAART who had structured treatment interruptions during the acute phase but the 
benefits in chronic HIV-infection are less clear (Rosenberg et al, 2000 and  Lori et al, 2000). 
 
Although the outcome of STIs is qualitatively different in acute and chronic HIV-1 infection, 
it was originally thought that STIs in HIV-1 infected subjects would be successful.  However 
patients lost control and had to restart therapy (Altfeld & Walker, 2001). Early ARV therapy 
in acute HIV-1 infection generates strong HIV-specific CD4+ T-cell responses and the viral 
load decreases with each HAART cycle (Fig 6a) whereas ARV therapy in chronic HIV-1 











                               
                          
 
Figure 6: a) STI in acute and early HIV-1 infection. The goal is to achieve long-term 
immune control of viral replication. b) STI in chronic HIV-1 infection responding to 
HAART. The goal here is to reduce the toxicity and cost of drugs.  
Adapted from: Lisziewicz and Lori, 2002 
 
 
(6a)                           
 
(6b)                           
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Pilot studies on small cohorts showed that STI in chronic HIV-1 infection can augment virus 
specific immune responses in most individuals and these augmented responses were 
associated with lower levels of plasma virus (Altfeld et al, 2001), but these studies were 
undertaken in adults. In contrast while control was not long lived, STIs in adult chronic 
infection has shown to be detrimental (The SMART Study Group, 2006), however the use of 
STIs in children with chronic HIV-1 infection, has not been widely investigated. Although 
STIs have been used in many adult acute and chronic studies, the use in children has been 
limited especially when investigating immune responses. There were limited studies 
performed by Feeney et al. (2003a) and Thobakgale et al. (2007). 
  
1.5 HIV Vaccines  
 
Although effective medical treatments for HIV exist, it is generally acknowledged that an HIV 
vaccine is the only alternative that would bring this pandemic to a halt. Currently, no effective 
vaccine has been developed. 
 
HIV infection results in a progressive decline in CD4+ T-cell number and function, thus 
resulting in an increased risk of opportunistic infections (Elrefaei et al, 2004). The HIV-1 
epidemic still remains a global challenge with rapid and continual spread, especially in the 
developing countries. Despite the existence of HAART, which has helped to curb the rates of 
disease progression, the mortality rate due to the HIV-1 epidemic, is astoundingly high 
(Garber et al, 2004). The high prevalence amongst the antenatal clinic attendees has brought 
overwhelming insight into the burden of new HIV infections that occur in developing 
countries. Therefore the challenge is to design a vaccine that would be safe, effective, 
affordable and simple to implement in developing countries.   
 
However, despite the enormous amount of research already done with regards to vaccine 
development, success has proven difficult. This is due to the complex structure of the HIV 
envelope glycoprotein, which is resistant to antibody neutralization and has the capacity to 
rapidly evolve to escape from whatever antibody responses are mounted by the infected 
individuals (Garber et al, 2004).  The rapid evolution of HIV within infected individuals is 
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one of the factors that have contributed significantly to the slow progress in the development 
of an effective HIV vaccine.  
 
In February 2003, the AIDSVAX vaccine that targets the gp120 region of the HIV genome 
was declared a failure in North America as there was not a statistically significant reduction of 
HIV infection within the study population (Francis et al, 2003). In November 2003, the 
AIDSVAX vaccine failed in Thailand for the very same reason as in North America 
(McCarthy et al, 2003) The ALVAC vCP1521 canary pox vector/AIDSVAX prime-boost 
vaccine trial in Thailand provided interesting results in that CTLs from the volunteers were 
able to kill PBMCs infected with primary isolates of HIV (Kantakamalakul et al, 2004). It was 
also the first vaccine to induce cross-clade functional CTL response.  
 
In December 2004, the V520 vaccine trial was introduced in North and South America, the 
Caribbean and Australia. This vaccine was intended to prompt the body to produce T-cells 
that kill HIV-1 infected cells. In fact the V520 vaccine failed to confer protection against 
HIV-1. It actually increased the odds of becoming infected with HIV-1 (White, 2008). 
 
 In February 2008, a major vaccine trial in South Africa, which used the Merck MRKAd5 
vaccine, was brought to a complete halt after vaccines in the sister trials in Australia and the 
USA were declared ineffective as the vaccine which contained three genes in a weakened 
adenovirus, had made the study participants in the vaccine arm more likely to become infected 
with HIV compared to placebo recipients in the vaccine trial (Health News, 2008). 
 
It is hypothesized that for a vaccine to be effective, CD8+ T-cell (CTL) based AIDS vaccines 
will probably need to suppress the extent of HIV replication from the earliest stages of 
infection, in order to limit the generation of immune escape variants. Furthermore the CTL-
based AIDS vaccine will need to elicit responses against multiple HIV epitopes (Altman et al, 





1.6 The SMART study 
 
 
The Strategies for the Management of Antiretroviral Therapy trial was designed to investigate 
the use of episodic antiretroviral therapy as compared to the continuous antiretroviral therapy. 
The protocol for the trial involved interrupting therapy when the CD4 count was 350 cells/ml 
and to resume therapy when the CD4 count fell below 250 cells/ml. The theory behind this 
trial was that the association between CD4 count and the risk of clinical disease from a large 
number of studies suggested that people who start antiretroviral therapy early in HIV-1 
infection could safely interrupt therapy for prolonged periods of time without obvious harmful 
consequences. (The SMART Study Group, 2006).  
 
The SMART Trial was the largest treatment strategy trial ever undertaken. It began in 2002 
and enrolled 5, 472 participants from 318 clinic sites in 33 countries. In January 2006, the 
Data and Safety Monitoring Board (DSMB) recommended that the trial stop due to the fact 
that the risk of disease progression to the participants in the episodic treatment arm of the trial 
was twice as high as the participants in the continuous therapy arm of the trial. There was also 
an increase in major complications such as cardiovascular, kidney and liver diseases in the 




1.7 Rationale of the Paediatric Antiretroviral (PARV) study 
 
At the time that this study was initiated, there was little evidence for the non-effectiveness of 
structured treatment interruptions (STI) in chronic HIV-1 paediatric infection. Most of these 
HIV-infections in children are acquired through perinatal transmission, (i.e. during the 
development of their immune system) therefore the clinical manifestations of the infection and 
the course of immunological and virological markers may differ from those of adults. Clinical 
efficacy of HAART in children has been well documented in industrialized countries, (Viani 
et al, 2004; Gortmaker et al, 2001; Van Rossum et al, 2002). Although there had been a few 
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studies of STI in adult cohorts, studies of STI in children particularly in African countries, had 
not been well investigated.  
 
Therefore this pilot study focused on a chronic HIV-1 paediatric cohort from Durban 
(KwaZulu-Natal, in South Africa) to assess the immunological and virological responses in 
perinatal HIV-infected children undergoing structured treatment interruptions (STIs) and to 
determine whether treatment interruptions would effectively boost and broaden the CTL 
responses in chronic HIV-1 paediatric infection.  
 
The aim of this study was to assess the magnitude and breadth of HIV-specific T-cell 
responses before and during HAART in chronic HIV-1 infection in children and to describe 
the pattern of these responses in children who underwent Structured Treatment Interruptions. 
The enrolled children were followed up for a period of 24 months. The objectives of this study 
were to determine the CD4 percentages and estimation of the viral load for all visits, to 
characterize HIV-1 specific CD4+ and CD8+ T-cell responses in these chronic HIV-1 infected 
children as well as to assess viral resistance patterns before they started HAART, during 
HAART and during the treatment interruptions, and finally to determine the response to 
antiretroviral treatment and whether HIV-specific T-cell responses were associated with 
control of viraemia. 
 
 
1.8 Specific Aims 
 
· To characterize HIV-1 specific CD4+ and CD8+ T-cell responses in this cohort 
· To determine changes in the CD4 % and viral load during HAART and STI 
· To assess viral resistance patterns before, during HAART and during STIs 
· To determine response to HAART and whether HIV-specific T-cell responses were 







1.9 Hypotheses and Rationale 
 
Hypothesis: Short-term HAART in chronically infected children boosts HIV-specific T 
helper responses, and therefore improved immune control of HIV is reached during STI.   
Rationale: 
1. The course of HIV-1 infection differs significantly between adults and children. 
Children, in part due to the immaturity of the immune system at the time of infection, 
typically control viraemia poorly. In part, this is a result of impairment of T-cell 
function. 
 
2. HAART initiated in chronic paediatric infection, but not in chronic adult infection, has 
been shown to increase levels of HIV-specific CD4+ T helper responses (Feeney et al, 
2005). Thus, short-term HAART, followed by STI, might be expected to allow older 
children to generate more effective HIV-specific T-cell responses than without the 
period on HAART.  
 
3. Structured Treatment Interruptions provide an attractive alternative to continuous 
therapy, which has its own particular problems in paediatric infection, in particular 
compliance/adherence, availability of paediatric formulations of anti-HIV drugs, and 
the need to frequently alter drug dose to keep track with growth and weight changes in 
childhood.  
 
4. A major concern of STI is the possibility that the “on/off” cycles of treatment may 




1.10 Ethical Approval 
 
Ethical approval for the study was obtained in 2002 from the Biomedical Research Ethics Committee 





2.1 STUDY DESIGN 
 
Thirty children who satisfied the inclusion criteria were enrolled into the study. Upon 
enrollment, they were randomized to either the Treatment Interruption Arm (TAT) or the 
Continuous Treatment Arm (CAT).  
 
Figure 7 is a schematic representation of the study design. All children received the triple 
antiretroviral therapy combination (AZT/3TC/ABC) for six months. The children randomized 
to the CAT Arm, continued with the regimen to the end of the study period (two years), 
whereas those randomized to the TAT Arm, stopped the triple antiretroviral treatment if their 
viral load was undetectable. Viral loads were monitored weekly.  
 
 
Figure 7.  Schematic representation of the design of study. 
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The course of antiretroviral therapy was resumed for a period of three months if participant 
viral load increased by one log value. These cycles continued throughout the study period 
(two years). 
 
After six months of antiretroviral treatment, children in the TAT arm, who had a detectable 
viral load, continued with antiretroviral treatment for a further six months (received treatment 
for a period of 48 weeks). After forty-eight weeks of antiretroviral treatment, children who 
had an undetectable viral load followed the interruption protocol with repeated cycles. 
Children with detectable viral loads after 48 weeks of antiretroviral treatment were screened 
for antiretroviral drug-resistance mutations. 
 
The visits for all children were scheduled as follows: 
· CAT Arm – baseline (pre-HAART); 12 weeks; 24 weeks; 48 weeks; 72 weeks and the 
final visit at 96 weeks. 
· TAT Arm – baseline (pre-HAART); 12 weeks; 24 weeks; 48 weeks; 72 weeks; weekly 
during the treatment interruptions and a final visit at 96 weeks. 
 
 
2.1.1 Study site and inclusion criteria for enrolment  
 
Chronic HIV-1 infected children attending the Family Clinic at King Edward VIII Hospital in 
Durban were recruited between January 2004 and November 2004, after they met the 
inclusion criteria for the study. 
 
 
Inclusion Criteria for Study:  
 
· Chronic HIV-1 infected children with post test counseling and informed consent of a 
responsible parent or guardian   
· Age: 2 – 12 years  
· Resides at a fixed address and within an accessible area in the Durban Metropolitan 
region. 
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· ART naïve (Infants who had received a single dose nevirapine in the MTCT program 
were not excluded) 
· To have had no other illness at the time of enrolment  
· Must be in category B according to the CDC guidelines 
 
 
2.1.2 Informed Consent 


















2.2 SAMPLE COLLECTION AND LABORATORY METHODS 
 
2.2.1.1 Blood sample collection 
 
Approximately 8mls of whole blood sample were collected in a 10ml EDTA anticoagulant 
tube at the baseline visit for the following tests: a CD4 cell count, full blood count (FBC), 
isolation of DNA, isolation of plasma for RNA-PCR, isolation of peripheral blood 
mononuclear cells (PBMCs) for use of ELISpot screening and Intracellular Cytokine Staining 
(ICS). Where insufficient amounts PBMCs were recovered, the ELISpot and ICS tests were 
performed at the next visit. Figure 8 is an illustration of the different tests that were performed 
on the blood sample of each participant.  
 
Blood samples were collected at the following time points: 12 weeks, 24 weeks, 48 weeks, 72 
weeks and 96 weeks for the children who were randomized to the continuous treatment arm of 
the study. The children who were randomized to the structured treatment interruption (STI) 
arm of the study, had blood samples collected at the 12 week and 24 week time points for 
immunology studies. Following the STIs, ~5mls of whole blood sample was collected weekly 
for a CD4 cell count and viral load measurement.  
 
 
2.2.1.2 Laboratory Testing  Criteria 
 
a) CD4 cell counts and viral load measurements were performed for all children at all 
timepoints. This included the time off treatment period. 
 
b) The ELISPOT test was performed at baseline, 12 weeks, 24 weeks, 48 weeks and 96 
weeks for the children in the continuous treatment group. The children in the treatment 
interruption group had ELISPOT tests done at baseline, 12 weeks, 24 weeks, 48 week, 
96 weeks and at all timepoints (where PBMCs were available) during the period off 
treatment. 
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c) The ICS test was performed for all children at varying timepoints due to the 
availability of PBMCs. 
 
d) HIV resistance tests were performed on all samples obtained at baseline, during the 
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Cytokine Staining  
Figure 8.  Schematic representation of the tests performed on the 
participant’s blood sample 
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2.2.2 CD4+ T-cell count 
 
Principle: Immunophenotyping involves the identification and enumeration of targeted cells 
in whole blood samples using immune cell markers expressed by the cell. Fluorochrome-
labeled antibodies bind specifically to the leukocytes of the whole blood. The erythrocytes 
were lysed prior to flow cytometry analysis on a FACS Calibur flow cytometer (Becton 
Dickenson Immunocytometry Systems, San Jose, CA). 
 
Safety: All blood specimens, reagents and controls were considered biohazardous and 
infectious. When working within the biosafety cabinets, a Howie lab coat including double 
gloves, were worn.  When using the FACS calibur a lab coat, gloves and eye goggles were 
worn when loading samples. The antibody reagents contain sodium azide as a preservative. 
The Lysing Solution contains diethylene glycol and formaldehyde. 
 
Sample preparation: The BD MultiTESTTM CD3 fluorescein isothiocyanate (FITC)/ CD8 
phycoerythrin (PE)/CD45 peridinin chlorophyll protein (PerCP)/CD4 allophycocyanin (APC) 
is a four-color direct immunofluorescene reagent used with the TruCOUNT Tubes which 
contains a freeze-dried pellet of fluorescent beads. This kit was stored at 4oC. 
  
· The antibody and the required number of TruCOUNT tubes were removed from the 
fridge and allowed to stand for a few minutes at room temperature. 
· A 1:10 dilution of working FACS Lyse solution was prepared (Appendix 2).   
· The TruCOUNT tube was labeled with the sample identification number and the date.  
· The antibody was vortexed for ~5 seconds and 20µL was pipetted into each of the 
TruCOUNT tube. The tube was gently tapped to allow the antibody to mix with the 
bead pellet.  
· The whole blood was then vortexed and 50µL was pipetted into the respectively 
labelled TruCOUNT tube.  The TruCOUNT tubes were capped, vortexed for ~3 
seconds.  The tubes were then covered with tin foil (to allow for the incubation for 15 
min at room temperature in the dark). 
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· On completion of the incubation, 450µL of the working FACS Lyse Solution was 
added to each tube.  The tubes were capped and vortexed for ~3 seconds. The tubes 
were then covered with tin foil for 15 min at room temperature (to allow for the Red 
blood cells to lyse). 
· The remaining blood was kept in the BSC until the CD4 assay had been completed. 
On completion of the analysis, the samples were discarded appropriately. 
 
Internal quality control:  The IMMUNO-TROLTM cells from Beckman Coulter are an 
assayed, lysable whole blood quality control sample that was processed with every batch of 
test samples.  The IMMUNO-TROLTM cells provided optimization of the instrument settings 
and performance. 
 
 Calibration of Equipment:   The CaliBRITETM Beads from Becton Dickenson was used to 
calibrate the FACS Calibur flow cytometer. Calibration allowed the photomultiplier tube 
(PMT) voltages and the fluorescence compensation to be set and also checked the sensitivity 
of the instrument. 
 
Analysis of samples: The samples were analyzed on the FACS Calibur flow cytometer with 
the MultiTEST SOFTWARE (version1. 1.2). Manual gating of each sample was performed if 
necessary. A printout out for each of the test sample and control sample was generated.  
 
Cleaning and shutdown of the FACS Calibur Flow Cytometer: Once all the samples had 
been analysed, the flow cytometer automatically goes into a cleaning program. On completion 
of the cleaning cycle, the flow cytometer is depressurized and a worklist summary report was 
printed and filed. The analyzed samples were removed from the flow cytometer, capped and 
discarded into the biohazardous waste disposal buckets. The tube with distilled water was 






2.2.3 Separation and storage of plasma 
The whole blood samples were centrifuged at 1700 rpm for 10 minutes at room temperature. 
The plasma was recovered with a sterile Pasteur pipette under sterile conditions and aliquoted 
into sterile internal thread cryovials and stored at –850C until required. 
 
 
2.2.4 HIV-1 RNA-PCR Quantification (viral load) 
The viral loads for this pilot study were initially performed at the Africa Centre Laboratory. 
Due to the changes within the Africa Centre Department, the viral loads were no longer 
performed at the Africa Centre Laboratory. Continuation of the viral load testing was 
performed at the HPP Laboratory from November 2004 until the end of the study. 
 
 
2.2.4.1 NucliSens®: Lysis buffer, magnetic extraction reagents and 
NucliSens EASYQ HIV-1 version -1.2 (Biomerieux) 
 
Principle:  The Nucleic acid extraction method is based on magnetic silica particles. Nucleic 
acids bind to the silica particles under high salt concentrations. The silica acts as a solid phase 
and non-nucleic acid components are removed by several wash steps using the miniMAG. 
The nucleic acids are eluted from the solid phase. NucliSens EasyQ HIV-1 v1.2 reagents are 
used for the nucleic acid amplification and detection assay for the quantitative determination 
of HIV-1 RNA in human plasma. The HIV-1 viral loads that can be measured in this assay 
range from 51 – 5,390,000 RNA copies/ml.  
 
EASYQ HIV-1 NucliSens Magnetic Extraction: 
200µl of plasma sample was added to a 2ml aliquot of NucliSens Lysis Buffer in a 15ml 
Falcon tube. This was vortexed and left to incubate for 10mins at room temperature. 220µl of 
elution buffer was then added to the calibrator (to reconstitute the lyophilized pellet) and this 
was vortexed thoroughly. 20µl of the reconstituted calibrator was added to the test sample and 
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vortexed followed by the addition of 50µl of vortexed silica. The tube was then vortexed 
thoroughly and incubated for 10mins at room temperature, thereafter centrifuged for 2mins at 
1500g. The supernatant was then removed with a pastette and 400µl of wash buffer 1 was 
pipetted into the sample tube. The wash buffer was mixed with the pellet and this was then 
transferred to a sterile 1.5ml starsted tube using a sterile pastette. After 30 rotations on the 
miniMag, the supernatant was removed and the wash step was repeated. After 30 rotations, 
the supernatant was removed and two wash steps were done with 500µl wash buffer 2.  After 
the supernatant was removed, the final wash was done with 500µl wash buffer 3. The 
supernatant was removed after 15 rotations on the miniMag. 25µl of the elution buffer was 
added to the tube and incubated at 600C for 5mins on a shaking incubator. This was followed 
by the removal of the silica using the miniMag. The extracted RNA was then transferred to a 
clean 1.5ml starsted tube. 
 
Preparation of mastermix: 
ENZYME: 45µl of Enzyme Diluent was added to the lyophilized pellet. After a gentle mix, 
the tube was left at room temperature for 15mins. 
PRIMERS: 90µl of Primer Diluent was added to the lyophilized pellet and vortexed 
immediately.  
 
Amplification and Detection: 
5µl of the extracted RNA was aliquoted into the correctly labeled 8-tube strip. This was 
followed by the addition of 10µl of the primer. The strip was placed in the NucliSens EasyQ 
Incubator and the programmed for 1min at 650C, then 2mins at 410C. Thereafter 5µl of the 
enzyme solution aliquoted into the each of the caps of the strip, the strip was then capped and 
centrifuged (pulse spin) in the Mini-Strip Centrifuge. The strip was then transferred to the 
NucliSens EasyQ Analyser for amplification and detection. The results of the test samples 
were printed in a numerical format. 
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Internal quality control:  The EASYQ HIV-1 NucliSens Magnetic Extraction is designed 
such that each run comprises of 8 tests. There were no individual control samples; however, 
the calibrator was incorporated with the test sample. If the calibrator failed then that particular 
test sample was repeated. 
   
2.2.4.2 Cobas amplification HIV-1 Monitor test, version -1.5 (Roche 
Diagnostics) 
 
Principle:  The COBAS AMPLIFICATION HIV-1 MONITOR TEST, version-1.5 is an in 
vitro nucleic acid amplification test for the quantification of HIV-1 RNA in human plasma on 
the COBAS AMPLICORTM ANALYZER. The Test can quantitate HIV-1 RNA over the range 
of 50-750 000 copies/mL by using a combination of two specimen preparation procedures 
namely the Standard and the UltraSensitive procedures (Roche Diagnostics, Germany).   
 
The Cobas amplification HIV-1 monitor test is based on five major processes: 
· Specimen preparation 
· Reverse Transcription (the target RNA is transcribed into cDNA) 
· PCR Amplification (target cDNA used HIV-1 specific complimentary primers) 
· Hybridization (of the amplified products to the oligonucleotide probes specific to the 
target) 
· Detection (of the probe-bound amplified products by colorimetric determination) 
 
Standard procedure (HIM test)  
Preparation of mastermix (in pre-amplification room) 
100µL of the HIV-1 Mn 2+ solution was added to one vial of the HIV-1 MMX solution and 
mixed well by inverting the tube (working HIV-1 MMX). 50µL of the working HIV-1 MMX 
was added to each of the 12 A-tubes of the A-ring. The A-ring was stored in the fridge (up to 
4 hours) in a reseal-able bag, until use. 
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HIV-1 RNA Extraction from the controls and test samples (Performed in the HPP 
Virology Laboratory in a Biological Safety Cabinet) 
A 2ml starsted tube was used for each of the three controls (Negative, Low Positive and High 
Positive Controls) and test samples processed. The precipitate that formed in HIV-1 LYSIS 
Buffer upon storage at 2-80C, was dissolved (by warming it up to room temperature). The 
working Lysis Buffer was prepared by adding 100µl of HIV-1 MONITOR Quantitation 
Standard (HIV-1 QS) to the vial of HIV-1 Monitor Lysis Reagent. The working Lysis Buffer 
was mixed well and 600µl was aliquoted into each tube. 200µL of Normal Human Plasma 
(NHP) was added to each of the control tubes and 200µL of patient’s sample to the respective 
tubes. 50µL of the controls were added to the respective control tubes. 
 All tubes were vortexed and incubated for 10 minutes. 800ul of 100% iso-propanol was 
added to each tube which was then vortexed and centrifuged for 20 minutes. The supernatant 
was discarded and the pellet was washed with 1ml of fresh 70% ethanol (Appendix 3). The 
tubes were vortexed and centrifuged for 5 minutes. The supernatant was discarded and the 
pellet was clearly visible. Thereafter 400µL of HIV-1 Monitor Specimen Diluent was added 
to each tube. 50µL of each processed controls and specimens were added to the appropriately 
labeled A- tube in the A-ring (which contained the working MMX solution). 
Detection and Quantitation of HIV-1 RNA: The A-ring was transferred to the Roche Cobas 
Amplicor Machine where the process of reverse transcription, amplification, hybridization 
and detection was performed. The COBAS AMPLICOR HIV-1 MONITOR TEST KIT 
quantitates the HIV-1 viral RNA and utilizes the HIV-1 Quantitation Standard which was 
added to the test specimen of a known concentration. The results of the controls and test 
samples were printed in an exponential format. 
Internal quality control:  The COBAS AMPLICOR HIV-1 MONITOR TEST KIT is 
designed such that each run (12 tests) would include three controls (Negative, Low positive 
and High positive control) and nine test samples. All controls must be within the range 
stipulated by the COBAS AMPLICOR HIV-1 MONITOR TEST KIT. If any of the controls 
 41
failed to meet the stipulated criteria of the TEST KIT, the entire assay would have to be 
repeated. 
   
2.2.5 DNA isolation  
DNA was isolated from the sample with the PUREGENETM DNA ISOLATION Kit (Gentra 
Systems, Minneaplois, USA). The Kit consisted of five processes namely; 
 
Red Blood Cell Lysis:  9ml of RBC Lysis Solution (Appendix 4) was added to ~3ml of the 
blood sample (after the PBMCs were removed). The tubes were inverted and left to incubate 
for 10 minutes at room temperature. After centrifugation at 2000 rpm for 10 minutes, the 
supernatant was poured out. (This step was performed twice, to ensure the recovery of the 
white blood cells only).  
 
Cell Lysis: The excess supernatant was removed with a fine tip Pasteur pipette. After which 
the pellet was disrupted by vigorous motion of the tube along the surface of a tube rack.  
3mls of Cell Lysis Solution was added to re-suspend the cells. The sample was left to 
incubate at room temperature for at least 24 hours. 
 
Protein Precipitation: The proteins were precipitated with the addition of 1mL Protein 
Precipitation Solution to the cell lysate.  This was vortexed for ±20 seconds and centrifuged 
at 2000 rpm for 10 minutes.  The precipitated proteins formed a tight, dark brown to reddish 
pellet.   
 
DNA Precipitation: The supernatant which contained the DNA was removed with a Pasteur 
pipette, and put into a clean tube (labeled with the sample identification no. and date), which 
contained 3mls of 100% iso-propanol (the precipitated protein pellet was left behind). The 
tubes were inverted ± 30 times, until white threads of DNA formed a visible clump. If no 
strand of DNA was seen, it was noted on the side of the tube. The DNA formed a small 
visible white pellet at the bottom of the tube after centrifugation at 2000 rpm for 3 minutes.  
The supernatant was poured off and the pellet was then washed with a 3ml 70% ethanol 
solution (Appendix 3). The supernatant was poured off again and the excess drained on clean 
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absorbent paper after it was centrifuged at 2000 rpm for 1 minute. The DNA pellet was left to 
air dry for ± 15 minutes.  
 
DNA Hydration:  Approximately 50 µl of DNA hydration solution was added to each tube. 
(This was based on the actual size of the DNA pellet). Samples were left at 40C for at least 24 
hours before it was pulse centrifuged and aliquoted into pre-labeled (with the specific sample 
identification no, date of receipt and the specific time point) 1.5 ml eppendorf tubes and 
stored in at -200C until required. 
 
DNA Measurement: Prior to the use of the required DNA samples, the samples were 
removed from the -200C freezer and thawed at room temperature for a few minutes and then 
gently vortexed at a low speed. A sample volume of 1 ul of DNA was measured at 260/280nm 
using a Nanodrop (ND-1000 Spectrophotometer - Inqababiotec™, Pretoria, South Africa).  A 
ratio of 1.8 was regarded as pure DNA.  
 
 
2.2.6 Peripheral blood mononuclear cells (PBMCs)  
 
2.2.6.1 Separation of PBMCs 
 
Principle: The HISTOPAQUE-1077 reagent was used for the isolation of mononuclear cells 
by density-gradient centrifugation. The blood sample was layered onto the HISTOPAQUE-
1077. During centrifugation, the erythrocytes and granulocytes were aggregated by the 
polysucrose and rapidly sediment; whereas the lymphocytes and other mononuclear cells 
remained at the plasma- HISTOPAQUE-1077 interface. The extraneous platelets were 
removed by the low speed centrifugation during the wash steps (Sigma-Aldrich, INC. St. 
Louis, USA).  
 
Safety: HISTOPAQUE-1077 solutions are harmful. It causes sensitization by 
inhalation and skin contact. A Howie coat and double gloves were worn when working 
with these solutions and effort was made not to breathe the vapours. 
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Reagent preparation:  The Histopaque-1077; PBS (Appendix 5) with antibiotics (Appendix 
6) and R10 (Appendix 7) media were removed from the fridge and left at room temperature to 
warm. The plasma from the whole blood samples were removed and stored prior to the 
separation of the PBMCs. The separation was based on a ratio of 1:1:1 of the HISTOPAQUE-
1077 : PBS+ANTIBIOTICS : BLOOD SAMPLE. 
 
Sample preparation: An equal volume of Histopaque-1077 was added to a sterile 15ml 
Falcon tube. The blood sample (buffy coat + red blood cells) was diluted with an equal 
volume of PBS+antibiotics (Appendix 6). This was mixed well and carefully layered onto the 
Histopaque-1077. The tubes were centrifuged at room temperature for 30 minutes at 1500 
rpm with slow start and the brakes off.   
 
 
                                            
Figure 9.  Illustration of the blood sample layered on the Histopaque® - 1077 
 
The mononuclear cell layer (opaque interface) was transferred into a sterile 15mL Falcon 
tube. PBS with antibiotics was added up to a volume of 13mL. The tubes were gently inverted 
and then centrifuged at 1500 rpm for 10 minutes at room temperature (first wash of the 
PBMCs). When decanting the supernatant it was ensured that the cell pellet was not disrupted. 
If red blood cells were present after the first wash step, a few drops of sterile distilled water 
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antibiotics for the second wash of the PBMCs. The supernatant was decanted and the tubes 
were tapped gently to break up the cell pellet and then resuspended with 10 mL of R10 
medium (Appendix 7).  The PBMCs was enumerated prior to the performance of tests 
performed. 
 
2.2.6.2 Enumeration of PBMCs 
PBMCs were initially counted with the Haemocytometer. This method proved to be time 
consuming and there was variation with the cell counts of samples. With the increase in the 
number of samples, the Guava Cell Counter (Guava Technologies INC, Hayward, CA 94545-
2991, USA) was purchased. The Guava Cell Counter proved to be useful for cell viability, 
counts over a wide range of cell concentrations and consistency. 
 
2.2.6.2.1 Haemocytometer – Cell counting 
 
Principle:  It is important to establish the concentration of the cells that you are working with. 
There are many applications that require specific cell counts eg. Intracellular Cytokine 
Staining, ELISPOT assays, freezing cells etc. 
 
Procedure: The isolated PBMCs were resuspended in 10 ml of R10 medium. The cells were 
thoroughly mixed with a pipette aid and a 10 ml pipette.  The tube was then vortexed and 
50µl of the cell suspension was aliquoted into a sterile 1.5 ml eppendorf. 50 µl of Trypan Blue 
was then added to the eppendorf and was then vortexed. 10µl of the diluted cell suspension 
was transferred into the well of the haemocytometer and was then placed under the 
microscope and the cells were counted. 
 
The cells were counted in two of the nine squares as shown in Figure 10. Cells were not 
counted if they touched the line that bordered the square or if they were between the two little 
squares as shown in Figure 10.  
       
 45
                          
 
Figure 10.  Schematic representation of the haemocytometre used for the counting of 
PBMCs. 
 
Enumeration of the cells:  
Cells per ml = the average count per square x dilution in trypan blue x volume of stock 
suspension x 104 
 
Example: First square        =  55 cells 
       Second square   =  49  cells  
  Average of both squares = 52 cells 
  x 2 for the dilution in trypan blue  = (52 x  2)  =  104 cells 
x 10ml (in which the cells were reconstituted) 
x 104 (for the volume of the haemocytomer chamber) 
= 52 x 2 x 10 x 104 cells/ml 
= 104  x 105  cells/ml 





2.2.6.2.2 Guava ViaCount – Cell counting 
 
Maintenance: The machine was turned on and left for at least 15 minutes to warm up. The 
waste bottle was emptied and »8ml of 2% Virkon (Appendix 8) was added. 
 
Guava Check: A 1:20 dilution of the Guava Check Beads (25 ml Beads to 475 ml Diluent) 
was freshly prepared and run three times on the Guava Cell Counter. The Guava Check 
Program was selected. Each reading of the beads must flag in green. If this was not the case, 
the clean cycle was selected and Guava Check Beads were rerun. If the Guava Check failed, 
the Guava Beads were re-prepared and read three times. 
 
Preparation of the samples: A 1:10 dilution of the PBMCs was prepared (20 ml of PBMCs 
to 180ml of Counting Solution). The diluted sample was vortexed thoroughly and incubated 
for 8 minutes at room temperature.  
 
Acquisition: The GuavaVia Count program was selected. The instrument was cleaned with 
Instrument Cleaning Fluid (ICF) on the clean cycle. The prepared samples were loaded 
individually on the instrument, the required patient data was entered and the cells were then 
acquired.  The instrument was cleaned twice with ICF and once with sterile distilled water 
before it was switched off. 
 
                                                                           
2.2.6.3 Freezing of PBMCs 
 
Purpose: Freezing of PBMCs was to allow for assays to be performed at a later date.  
 
Safety: A Howie coat and gloves were worn as well as cryogenic gloves and a face shield or 
goggles when working with the frozen cells and when using the liquid nitrogen freezer.  
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Procedure:  20ml of PBMCs was added to 180ml of Guava ViaCount Reagent. The PBMCs 
count was obtained using the Guava Cell Counter. The 15ml falcon tube that contained the 
cells was centrifuged in a chilled (40C) centrifuge for 5mins at 1700 rpm. The supernatant was 
removed with a volume of 200ml left behind. The pellet of cells was then resuspended in this 
volume. Based on the cell count, the cells were frozen at a concentration of 10 million cells 
per vial in a 1ml volume using 10% DMSO added to 100% Fetal Calf Serum. To reduce 
shock to the cells, half the quantity of freezing solution was added as FCS on its own and the 
cells were thoroughly suspended in this formula. Thereafter the FCS with DMSO was added 
in a drop-wise manner whilst gently shaking the tube. The cryovials were immediately 
transferred to the Mr. Frosty stratacooler box (which contained 100% isopropanol) and this 
was placed in the –85% freezer overnight. The following day the cryovials were transferred to 
the liquid nitrogen freezer. 
 
 
2.2.7 Intracellular Cytokine Staining (ICS) 
 
DAY 1 
The isolated PBMCs were counted and resuspended to a final concentration of 1 X 106 
cells/ml. A positive control sample (where 10 µl of PHA was added) and a negative control 
sample (where 10 µl of R10 media was added) were prepared with each test sample.  
 
A mastermix solution was prepared (per tube) with the following:  
· 1µl of anti-CD28 antibody (Becton Dickenson Immunocytometry Systems, San Jose, 
CA) 
· 1µl of anti-CD49d antibody (Becton Dickenson Immunocytometry Systems, San Jose, 
CA)                                                         
· 500µl of R10 (Appendice 7) 
 
The mastermix was vortexed and 500µl was aliquoted into each tube. 10µl of the Gag-pool of 
peptides was added to the test sample and 10µl of PHA to the positive control tube. 500µl of 
the PBMCs suspended in R10 media at a concentration of 1 X 106 cells/ml was added to each 
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tube. The tubes were incubated for 60 minutes at 37 0C in a 5% CO2 incubator. (The lids of 
the FACS tubes were loosened to allow the cells to breathe). Following the 60 minute 
incubation, 10µl of 1mg/ml Brefeldin A (Sigma Chemical Co., St Louis, USA) was added to 
each tube. (Brefeldin A prevented the secretion of cytokine IFN-γ during the cell activation to 
be transported outside of the cell). The tubes were incubated for 4.5 hours at 37 0C in a 5% 
CO2 incubator (a total of 6 hours from the start). The tubes were then refrigerated at 40C 
overnight and processed the following day. 
 
DAY 2 
2 mls of sterile PBS was added to each tube to resuspend the cells. The tubes were centrifuged 
at 2000 rpm for 8 minutes.  
 
Wash Step: 
The tubes were removed as soon as the spin was complete (cells would die if left longer that 
the specified time) and the PBS was removed by the inversion of the rack over the waste 
container (making sure not to disrupt the pellet). 
 
The tube with pellet was vortexed gently. The wash step with PBS was repeated twice.  
After the second wash, a mastermix solution of the following fluorescent cell markers was 
prepared: 
· 2µl anti-CD8-APC antibody (Becton Dickenson Immunocytometry Systems, San Jose, 
CA) 
· 1µl anti-CD4-PE antibody (Becton Dickenson Immunocytometry Systems, San Jose, 
CA) 
· 47µl chilled PBS 
 
50µl of antibody mastermix was aliquoted into each tube. The tubes were gently vortexed and 
incubated at 40C in the dark for 15 minutes. Followed by the wash step. 
 
2mls of PBS was added to each tube and centrifuged at 2000 rpm for 8 minutes. The tubes 
were removed as soon as the spin was completed and the PBS was removed by the inversion 
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of the rack over the waste container (be sure not to disrupt the pellet). 100µl of Fix/Perm 
Medium A (Caltag Laboratories, Burlingame, CA) was aliquoted into each tube and vortexed 
gently. The tubes were incubated for 15 min at room temperature in the dark (covered with tin 
foil), followed by the wash step. 
2mls of PBS was added to each tube and centrifuged at 2000 rpm for 8 minutes. The tubes 
were removed as soon as the spin was completed and the PBS was removed by the inversion 
of the rack over the waste container (be sure not to disrupt the pellet). 100µl of Cell 
Permeabilization Medium B (Caltag Laboratories, Burlingame, CA) and 6µl of anti-IFN-γ 
(Becton Dickenson, USA) was aliquoted into each tube. The tubes were vortexed gently and 
incubated for 20 mins at 4 0C in the dark, followed by the wash step. 
 
2mls of PBS was added to each tube and centrifuged at 2000 rpm for 8 minutes. The tubes 
were removed as soon as the spin was completed and the PBS was removed by the inversion 
of the rack over the waste container (be sure not to disrupt the pellet).  The tubes were gently 
vortexed and then resuspended in 200µl of PBS. The samples were acquired and analysed on 
the FACS Calibur Flow Cytometer. 
 
2.2.8 ELISPOT Assay 
Freshly isolated PBMCs were incubated overnight in a 96-well polyvinylidene difluoride-
backed plates (MAIP S45, Millipore) with 410 overlapping peptides (OLP) that spanned the 
entire HIV-1 genome ( Gag, Pol, Vif, Vpr, Vpu, Rev, Tat, Env and Nef). The PBMCs were 
screened in an Enzyme-Linked Immunospot (ELISPOT) assay, which was specific for IFN-g 
production. The amount of IFN-g secreted, was measured using an ELISA-based method. The 
ELISPOT plates were read using an automated reader (Autoimmune Diagnostics – Germany). 
 
Overlapping peptides: The panel of 410 overlapping peptides (OLPs) (15-18 amino acids in 
length and overlapped by 10 amino acids) were synthesized at the MGH Peptide Core Facility 
on an automated peptide synthesizer (MBS 396; Advanced Chemtech, Louisville, Ky.). The 
OLPs were arranged to form a matrix screen, where a positive response in two individual 
wells correlated to an individual peptide sequence. 
 
 50
The Peptide Matrix: The Gag, Pol, Env and Nef regions were represented as individual 
peptide matrices while the Rev, Tat, Vif, Vpr and Vpu regions were pooled into a combined 
accessory and regulatory protein peptide matrix as described previously for B Clade by Addo 
et al. (2003). Figure 11 is a representation of an ELISPOT plate showing the pooled peptides 
as well as some selected optimal optimals and the controls. 
 
 
Figure 11.  Pooled peptides in a matrix format on an ELISPOT plate that spanned the 
HIV genome. 
   
Peptide pools: The number of pools per protein matrix and the number of peptides per pool 
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The concentration of each peptide within a pool was 200µg/ml. Wells containing PBMC’s 
and R10 medium were used as negative controls and they were run in quadruplicate. 
Phytohaemaglutinin A (PHA) was added at a final concentration of 1.8µg/ml and run in 
duplicate to serve as a positive control. 
 
Positive Responses on ELISPOT Assay: Within the matrix, each peptide is contained in two 
different wells such that a positive response in two corresponding wells is linked to a single 
peptide (refer to figure 11). A positive response to a peptide was defined as response of ≥ 100 
spot forming cells (SFC’s) / million PBMC’s after subtraction of the background (mean 
SFC’s within the 4 negative wells to which PBMC’s were added and no peptide). Responses 
were excluded in the analysis if background exceeded 100 SFC’s / million PBMC’s or if the 
level of the peptide-specific response was less than the mean of the control wells plus three 
times the standard deviation of the IFN-γ production (SFC’s) within the control wells. 
 
Confirmation of Responses: Recognition of a pool of peptides was then reconfirmed using 
individual peptides in an IFN-γ ELISPOT assay. 
 
PROCEDURE   
DAY 1 
5µl of anti-human IFN-γ (Mabtech) was diluted with 10ml of Phosphate Saline Buffer 
(Appendix 5). The solution was vortexed thoroughly and 100µl was coated into the wells of 
the sterile 96-well polyvinylidene diflouride plate (Multiscreen, Millipore, Bedford, USA) 
with a multichannel pipettor. The plates were incubated overnight at 40C. 
HIV-1 Proteins No. of Peptides HIV-1 Proteins No. of Peptides 
Gag 66 Pol 133 
Neg 27 Vpr 11 
Rev 13 Env 113 
Tat 12 Vif 24 
Vpu 9   
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DAY 2 
The plates were removed from the fridge and washed six times with blocking buffer 
(Appendix 9). ~100µl of blocking buffer per well of each plate removed the unbound 
antibody. After the last wash step, 50µl of R10 medium was added to each well of the 
ELISPOT plate. For every patient’s cells tested, two wells contained 10µl of 
Phytohaemaglutinin A (PHA) at a concentration of (33.3µg/ml) as positive controls and four 
wells without any peptide as negative controls. 10µl of each peptide (33.3µg/ml) giving a 
final concentration of 2µg/ml was added to each well. 100µl of freshly isolated PBMCs 
suspended in R10 medium at a final concentration of 0.5 X 106 cells/ml was added to each 
well. The plate was incubated overnight at 370C in 5% CO2 incubator. 
 
DAY 3 
The cells were discarded into a disinfectant container which contained 2% Virkon (Appendix 
8). The plate was washed six times with PBS in the ELISPOT washer. 100µl of diluted 
Biotinylated anti-human IFN-γ (5µl of antibody to 10ml of PBS) was added to each well. The 
plate was incubated in the dark (covered with tin foil) at room temperature for 90 minutes. 
The plate was washed six times with PBS in the ELISPOT washer. 100µl of diluted 
Streptavidin-alkaline phosphatase conjugate (5µl of antibody to 10ml of PBS) was added to 
each well. The plate was incubated in the dark (covered with tin foil) at room temperature for 
45 minutes. The plate was again washed six times with PBS in the ELISPOT washer.  
 
Colour Development Reagents: 100µl of Bromo-Chloro-Indoylphosphate (BCIP) 
(Appendix 10) and 100µl Nitroblue Tetrozolium Chloride (NBT) (Appendix 11) was diluted 
in 10 ml of 1M TRIS Buffer  (pH = 0.3) (Appendix 12).  
 
100µl of the colour development reagent was added to each well of the plate which was 
incubated at room temperature until blue spots were seen (± 15 minutes). The development 
process was stopped by washing the plate at least six times under running water. The plate 
was left to air-dry on absorbent tissue paper. The ELISPOT plates were read using an 
automated reader (Autoimmune Diagnostics – Germany). 
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Table 2.  The instrument settings on the ELISPOT reader  
 
Parameter Instument settings 
Intensity 10 (min selected) 
Size 108 
Gradient 1 (min selected) 
Emphasis Tiny 
Max growth 30 
Max shrinking 10 
Max position change 50 
Correction method Find any ring shaped structure 
 
 
2.2.9 Human Leukocyte Antigen (HLA) typing 
 
Principle : The Dynal RELITM  SSO HLA Test (Dynal Biotech, Bromborough, UK) is a DNA 
based typing kit which provides a low to medium resolution HLA typing. Refining the 
genotype to the allele level was performed using the Dynal Biotech sequence-specific priming 
kits for the HLA-A, HLA-B and HLA-C loci. The test is based on four major processes i.e: 
(1) PCR target amplification; followed by (2) hybridization of the amplified products to 
immobilized sequence-specific oligonucleotide probes; (3) the detection of the probe-bound 
to the amplified product on nylon membrane strips by color formation; and (4) results 
interpretation. The HLA typing was performed according to the manufacture’s instructions 
and all the DNA samples were sent to the South African National Blood Transfusion Service 
where the assays were undertaken by personnel in the Transplant Laboratory.  
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PCR Amplification: 15µl of DNA (13-15 ng/µl ~ approximate 200ng/reaction) was added to 
the cocktail of 15µl of MgCl2 solution and 30µl of the HLA master mix, for each allele (HLA-
A, HLA-B and HLA-C), in sterile PCR tubes. A positive control (15µl of positive DNA 
control) and negative control (15µl of de-ionized water) was prepared, with each 
amplification assay set up. The tubes were capped and placed in the thermocycler and 
amplified on a selected program. 60µl of denaturation solution was pipetted into each PCR 
tube and incubated for 10 minutes at room temperature. 
 
Hybridization and Detection of the Strips: The labeled strips were placed in the typing tray 
with the probe lines facing upwards. 5ml of the pre-warmed working hybridization buffer 
(Appendix 13) was added to each strip followed by the 70µl of the correctly labeled PCR 
product. The strips were incubated for 30 minutes at 500C on a shaking platform. 
 
Two wash steps followed after the solution in each well was aspirated from each well. The 
first wash step was with 5ml of ambient wash buffer (Appendix 14) for 5 minutes at room 
temperature and second wash step with 5ml of pre-warmed stringent wash buffer (Appendix 
14) for 15 minutes at 500C.   
 
5ml of Conjugate Solution (Appendix 15) was added and the strips were incubated for 15 
minutes after the stringent wash buffer was aspirated. Two ambient wash steps were 
performed each with 5ml of ambient wash buffer and an incubation of 5 minutes after the 
conjugate solution was aspirated. 5ml of working citrate buffer (Appendix 16) was added 
after the wash buffer was aspirated and this was incubated for 5 minutes.  
 
After the citrate buffer was aspirated, 5ml of working substrate buffer (Appendix 17) was 
added to each well and incubated for 8 minutes. This was followed by two wash steps, each 
with 5ml of de-ionized water and incubated for 5 minutes. 5ml of Citrate buffer was added to 




Results Analysis: The strips were kept moist for the result analysis and then stored at 80C. 
The nylon membrane strips were analyzed using the RELI-ScanTM and Dynal Pattern 
Matching Program (PMP). 
 
 
2.2.10 HIV drug resistance and resistant mutations 
 
Resistance testing was performed on stored frozen plasma samples from thirty children 
enrolled to this study. The samples were sent to the National Institute for Communicable 
Diseases in Gauteng, South Africa where the assays were undertaken by personnel in the 
laboratory of Professor Lynn Morris.  
 
Genotyping: Sequencing of the HIV-1 pol gene was conducted using an in-house assay. Viral 
RNA was isolated from the stored plasma samples using the MagNa Pure automated system 
(Roche Diagnostics, Indianapolis, IN). A 1.7Kb fragment spanning the pol gene was 
amplified by nested PCR using the ThermoscriptTM RT-PCR System. 
 
PCR Primers:  
First round primers -  
G25REV (5’GCAAGAGTTTTGGCTGAAGCAATGAG3’)   
IN3  (5’TCTATVCCATCTAAAAATAGTACTTTCCTGATTCC3’) 
 
Second round primers –  
AV150 (5’GTGGGAAAGGAAGGACACCAAATGAAAG3’) 









Both the first and second PCR amplification conditions were identical. 
 
1 cycle  : 940C   : 2 minutes    
10cycles : 940C   : 10 seconds 
  : 500C  : 30 seconds 
  : 680C  : 2 minutes 
25 cycles : 940C  : 15 seconds 
  : 500C  : 30 seconds 
  : 680C  : 2 minutes  
    : 20 seconds for elongation on every cycle 
Final step  : 680C   : 7 minutes 
 
Sequencing: The PCR products were sequenced (codons 1-99 of protease and codons 1-350 
of reverse transcriptase) by using the BigDyeTerminators and an ABI 310 DNA Sequencer 
(Applied Biosystems, Foster City, CA).  
 
Analysis: Consensus sequences from all genotyped subjects were aligned and manually 
edited using the Sequencher version 4.5 program (GeneCodes, Ann Arbor, MI). Multiple 
alignments were performed using Clustal X. Phylogenetic analysis of nucleic acid sequences 
was performed with Mega version 3.1. Reference sequences were downloaded from Los 
Alamos (www.hiv.lanl.gov).  Genotypic resistance was defined as the presence of mutations 
associated with impaired drug susceptibility or virologic response as specified by the WHO 













3.1.1 Demographics and characteristics of participants 
 
 
Thirty chronically HIV-1 infected children were enrolled in the pilot study.  Immunological tests 
were performed on all children. However, these tests were not performed at all timepoints due to 
either insufficient peripheral blood mononuclear cells (PBMCs), disenrolment of children due to 









Thirty children were enrolled in the study. Fifteen children were randomized to the 
















(6.7%) child from the Treatment Interruption group of the study was disenrolled after two 
weeks due to sensitivity to the antiretroviral agent Abacavir (ABC). Eight (53.3%) 
children had treatment interruptions whilst the other six (40%) children did not undergo 
any treatment interruptions due to their detectable viral loads i.e. never reaching 
undetectable viral loads. 
 
The gender and age as well as the pre-treatment immunologic and virologic 
characteristics of the enrolled HIV-1 chronically infected children in the two arms of the 
study are depicted in Table 3. Statistical analysis of significance (P values) was 
calculated using the Mann Whitney test on GraphPad Prism. The P values indicated that 
there was no statistical significant difference with regard to gender, age, %CD4 T-cells, 
%CD8 T-cells and HIV-RNA log viral load, between the continuous therapy and 



































Interruption  Group 
 
p value 
No. of  Subjects  30 15 15 - 
Males 15 8 7 - 
Females 15 7 8 - 
Age in months: 
median (range) 60 (24-144) 72 (24-132) 58 (24-144) 
  
0.2354                          
     
CD4+ T-cell % : 
median (range) 18 (7-29) 18 (7-26) 17 (8-29) 
                          
0.9337                          
CD4+ T-cell count: 
median (range) 567 (218-1842) 567 (218-913) 533 (245-1842) 
 
0.8682 
     
CD8+ T-cell %: 
median (range) 47 (19-73) 46 (35-66) 47 (19-73) 
 
0.7394                          
CD8+ T-cell count: 
median (range) 1569 (559-8133) 1816 (559-2871) 1451 (808-8133) 
 
0.6186 
     
HIV-RNA  log10: 
median (range) 4.73 (3.60-6.00) 4.69 (3.62-6.00) 4.85 (3.60-5.83) 
                          
0.6934                          
        
 
Table 3. Demographic and clinical variables of the study participants in the continuous treatment 
group and the treatment interruption group at the pre-HAART timepoint   
 
 60 
3.1.2 CD4+ T-cell percentage and viral load estimation 
 
 
Immunological and virological parameters have been proposed as potential surrogate 
markers for viral replication (Ondoa et al, 2005). Immunological monitoring is an 
essential component in HIV clinical management. Monitoring tests assist in not only 
defining the stage of the infection but the need for antiretroviral therapy and monitoring 
the treatment thereof. HIV-specific CD4+ T-cells are likely to be the first to be activated 
in response to the virus however they become infected by the HIV and are destroyed. The 
CD4+ T-cell count and HIV-RNA (viral load) are considered to be the end-point 





3.1.2.1 CD4+ T-cell percentage and viral load estimation before 
starting and during early treatment with HAART 
 
Immune restoration Disease (IRD) may occur when the CD4 cell count rises rapidly 
during the first few months of antiretroviral therapy. Figures 13a and 13b demonstrate the 
%CD4 T-cells and the log viral load respectively for all patients at the pretreatment phase 






















Figure 13. Comparison of the %CD4 (a) and Log viral load (b) of the pretreatment 
phase (0 weeks) to the initial treatment phase (12 and 24 weeks). The yellow 
background indicates the treatment phase.  
 
The median %CD4+ T-cells increased from 18% before ARV treatment to 27% at 12 
weeks after ARV treatment (p value < 0.0001). %CD4+ T-cell recovery was maintained 
at 24 weeks (p value < 0.001). The median viral load decreased from log 4.70 to levels 
below detection limits by 12 weeks (p value < 0.0001) and was maintained at 24 weeks 
(p value < 0.0001). As depicted in figure 13b, 5/29 children had detectable viral loads at 
12 weeks (>log 2.60) and 9/29 at 24 weeks (>log 2.60). Hence not all children reached 
undetectable viral load levels by 24 weeks of ARV treatment. A possible reason why 
there was detectable virus at 24 weeks of ARV treatment could be that the initial viral 
load may have been extremely high (eg. in millions) so that it would have taken much 
longer than 24 weeks to reach undetectable levels, however this was the case for only one 
child as the viral loads for the other children were less than log 5. Three other 
possibilities include a) that the ARV treatment would have killed most of the susceptible 
virus, hence giving resistant virus a greater chance to replicate b) that the children may 
not have been adherent to the antiretroviral treatment and c) is that the HAART regime of 
3 NRTIs was not the ideal one. 
 
 































3.1.2.2 CD4+ T-cell percentage and viral load estimation in the 
continuous treatment group  
 
Figures 14a and 14b demonstrate the effect of continuous ARV therapy on %CD4+ T-
cells and viral load over a two-year period in HIV-1 chronically infected children (n=21). 
 
    (14a)       









































Figure 14(a). Demonstrates the pretreatment %CD4+ T-cell in relation to the 
%CD4+ T-cell over the two-year study period for the twenty-one children who 
received continuous ARV therapy (this includes the six children who did not have 
treatment interruptions but were randomized to the treatment interruption arm). 
The yellow background indicates the treatment phase. The change in the n values at 
48, 72 and 96 weeks, indicates the children who were disenrolled due to treatment 
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Figure 14(b).  The pre-treatment log viral load is shown in relation to the log viral 
loads over the two year study period for the twenty-one children who received 
continuous ARV therapy (this includes the six children who did not have treatment 
interruptions but were randomized to the treatment interruption arm). The yellow 
background indicates the treatment phase. The change in the n values at 48, 72 and 
96 weeks, indicates the children who were disenrolled due to treatment non-
adherence and development of drug resistance.  
 
The median %CD4+ T-cell increased from 18% before antiretroviral treatment to 35% at 
96 weeks (fig 14a). Six children (PARV 04, PARV 06, PARV 15, PARV 17, PARV 21 
and PARV 30) although randomised to the treatment interruption group, did not have any 
treatment interruptions due to their viral loads being detectable at 24 weeks. They 
therefore received continuous treatment for the study period. Two of the six children 
were monitored until 96 weeks and together with the other four children they were 
referred and subsequently monitored on the National Roll-Out Program. 
 
PARV 04, a five year old female child who had a 24% pre-HAART CD4% which 
increased to ≥30% up until 48 weeks on treatment. The pre-HAART viral load was log 
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4.76 which decreased to undetectable levels (log 2.09) at 12 weeks but was detectable 
(log 2.38) at 24 weeks therefore this child had to continue with the ARV treatment for 
another six months but the viral load was still detectable (log 2.97) at 48 weeks. 
Resistance testing was performed at this timepoint. The M184V mutation to 3TC had 
developed. This child also had a pre-HAART drug mutation G190EG to NNRTI.  
 
PARV 06, a four year old male child, had a low CD4 count (8%) and a high viral load 
(log 5.5) before starting antiretroviral treatment. Despite this severe deterioration of the 
immune system, with the antiretroviral therapy, a good increase of CD4 count (18%) was 
noted at 12 weeks after starting antiretroviral treatment. Although the CD4% maintained 
~20%, the viral load decreased to undetectable levels (log 2.09) at 12 weeks but was 
detectable (log10 = 4.20) and (log10= 4.08) at 24 and 48 weeks respectively. It was 
discovered that this child had contracted another viral infection about the 18th week on 
ARV treatment, and with a detectable viral load, scheduled treatment interruptions were 
not implemented. Resistance testing was performed and five new mutations (T215Y, 
M184V, M41L, D67N and K70R) had developed, because PARV 06 had no drug 
mutations prior to starting  HAART.  
 
PARV 15, an eight year old female child, had a CD4 count of 16% prior to starting 
HAART which increased to ≥26% during the 96 weeks of follow-up. The pre-HAART 
viral load was log 4.92 but reached undetectable levels at 12 weeks (log 2.09). At 24 
weeks the viral load increased to log  3.15 and continued to increase at 26 weeks (log 
3.26), 48 weeks (log 3.53) until 50 weeks (log 4.59). Resistance testing was performed 
and M184V mutation had developed, since PARV 15 had no drug mutations before 
starting HAART. However, at 72 weeks, the viral load reached undetectable levels (log 
2.09) but was detectable again (log 4.98) at 96 weeks.   
 
PARV 17, a two year old male child, had a CD4 count of 17% and a viral load of log 
4.85 before starting HAART. His CD4 count increased to 26% at 12 weeks on ARV 
treatment but his viral load did not reach undetectable levels (log 3.80). At 24 weeks his 
CD4 count was 24% and his viral load increased to log 5.65. A confirmation test was 
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performed at 28 weeks and his viral load was log 5.77. Resistance testing indicated that 
there were 4 mutations (M184V, K219N, D67N and K70R) that developed, as PARV 17 
did not have any drug mutations before starting HAART.  
 
PARV 21, a three year old female child, had a CD4 count of 12% and a viral load of log 
5.17 before starting HAART. Although her CD4 counts increased significantly until the 
end of the study period 96 weeks (≥24%), her viral load was undetectable at 12 weeks on 
treatment but increased thereafter throughout the rest of the study period. There were no 
drug mutations before starting HAART but three mutations (M184V, D67N and K70R) 
had developed after initiation of HAART.  
 
PARV 30 had a CD4 count of 18% before starting HAART. Although the CD4 count 
fluctuated a 10% increase was noted after treatment commenced. The pre-HAART viral 
load was log 5.04; however the viral load did not reach undetectable levels after 
treatment had commenced. Resistance testing indicated that M184V and Y181C drug 
mutations were present after the treatment had started as there were no drug mutations 
present before starting HAART. 
 
For most children (in this cohort) receiving continuous ARV therapy, % CD4+ T-cells 
increased steadily over the study period from a median of 18% to 35% in 13/15 children 
(Figure 14a). Two subjects had < 25% CD4+ T-cells even at 96 weeks of ARV therapy.  
One of the children had a very low CD4% before starting HAART and the other was 
treatment non-adherent.  ARV therapy suppressed viraemia to undetectable levels as 
early as 12 weeks post therapy and remained for the duration of the two-year study period 
in some children, whilst in some children undetectable levels were never obtained even 
after two years, due to drug resistant mutations arising. In other cases, children had 
suppressed viraemia, but there was a viral load rebound detected as a result of non-





3.1.2.3 CD4+ T-cell percentage and viral load estimation in the 
treatment interruption group  
 
Figures 15a and 15b demonstrate the effect of structured treatment interruptions on 
%CD4+ T-cells and viral load over a two-year period in HIV-1 chronically infected 






























































Figure 15.  Comparison of the pre-treatment %CD4 (a) T-cells and log viral load (b) 
in relation to the %CD4 and log viral load over the two-year study period for the 
children randomized to the treatment interruption arm.  
 
 
Although there were viral rebounds and small changes in the CD4 counts, overall at the 
end of the 2 year follow-up period, the CD4 counts and viral loads were consistent with 
good outcome. The CD4 count in the continuous treatment group was 18% at baseline 
and 35% at the end of the follow-up period and in the treatment interruption group it was 
20% at baseline and 30% at the end of the follow-up period. The log viral load decreased 
from 4.7 in the continuous group and 4.3 in the treatment interruption group to 
undetectable levels at the end of the 2 year follow-up period. 
(15a) (15b) 
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3.1.2.4 CD4+ T-cell percentage and viral load estimation in the eight 
children who had treatment interruptions  
 
Eight of the fifteen children who were randomized to the treatment interruption group 
had successful treatment interruptions. The interruptions were of a short duration (~ a 
week) for 5 children and varied (2-4 weeks) for the other 3 children. Figure 16 shows the 




























































Parv 03  (2 years, 7 months) 
































































































Parv 14  (6 years) 
























Parv 18  (2 years, 6 months) 





























































































Parv 26  (5 years) 
 
























Parv 28 (12 years) 























Parv 29  (8 years) 
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Figure 16. Longitudinal CD4% and log viral load of the eight children who had 
treatment interruptions. (a) PARV 03 (b) PARV 05 (c) PARV 14 (d) PARV 18 (e) 
PARV 19 (f) PARV 26 (g) PARV 28 and (h) PARV 29. The yellow background 
indicates the treatment phase. The age of the child represented, is the age when 
enrolled to the study at 0 weeks.     
 
PARV 03, PARV 05 and PARV 14 had 5 treatment interruptions. PARV 18 and PARV 
19 had 4 treatment interruptions. PARV 26 had 3 and PARV 28 and PARV 29 had 2 
treatment interruptions. A steady increase was seen in the %CD4 T-cells for all eight 






























3.1.2.5 Different CD4+ T-cell percentage and viral load estimation 
in the study cohort 
 
Figures 17a-d show examples of individual patients, from the continuous and structured 
treatment interruption arms, and the effects on the %CD4 as well as the log viral load, 
over the two study period.  
 
 
Figure 17a. The CD4% and Log Viral load of PARV 27 (11 years), who was 
randomized to the continuous treatment group.  The CD4% increased once 
treatment commenced (from 0 weeks) and steadily continued to rise throughout the 
study. The log viral load decreased from log 4.8 to an undetectable level and 
maintained undetectable levels throughout the study.   
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Figure 17b. In comparison to PARV 27, PARV 05 (2 years, 1 month) was randomized to 
the treatment interruption group and had five successful treatment interruptions. The 
CD4% increased once treatment commenced and despite the treatment interruptions, the 
CD4% did not reach pre-treatment levels. A steady increase throughout the study was 
noted. The log viral load decreased to an undetectable level by 12 weeks and was 
maintained at 24 weeks. The log viral load rebounded to detectable levels during the 
interruption periods hence treatment recommenced within a week of the interruptions for 
three months. The yellow indicates treatment phase.  
 
Figure 17c. The CD4% and Log Viral load of PARV 08 (4 years, 2 months). 
Although the Log viral load decreased and maintained undetectable levels by twelve 
weeks on antiretroviral therapy, there was a viral blip at 24 weeks. This was due to a 
Lower  Respiratory Tract Infection (LRTI). This child had a low CD4 count (7%) at the 
pre-HAART visit. Although the CD4% increased very slowly to 17% at 96 weeks, this 
child maintained undetectable levels of viremia with antiretroviral therapy.  
 
Figure 17d. The CD4% and Log Viral load of PARV 06 (4 years, 2 months). This 
child was randomized to the Treatment Interruption group but did not have treatment 
interruptions. Although the viral load was undetectable at 12 weeks, when tested at 16, 20 
and 24 weeks, the viral load was detectable. During this time it was established that this 
child had a chicken pox infection. Subsequently the viral load was still detectable at 48 
weeks and resistance testing was carried out and the results indicated that resistance had 
developed. Therefore it was decided by the study clinician and the Principal Investigators 
that it would in the best interest of the child to dis-enroll the child from the study and as 
the National Roll-Out Programme had just started it would be good to start the child with 
the regime that included a Protease Inhibitor. 
 
 
In this study there were no differences between the continuous and treatment interrupted 
groups with regards to the CD4 counts and viral load estimations at the end of the 2 year 
follow-up period. In addition there were no adverse outcomes in either of the groups in 
terms of death or other clinical outcomes. 
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3.2 ELISPOT T-CELL IMMUNE RESPONSES 
 
 
3.2.1 T-cell immune responses before HAART 
 
The enzyme-linked immunospot (ELISPOT) is a relatively simple assay for the assessment of 
pathogen-specific T-cell immune responses. The ELISPOT assay can detect virus-specific T-cells 
secreting cytokines at a single cell level (Czerkinsky et al, 1998 and Lalvani et al, 1997). 
Interferon-gamma (IFN-g) is the cytokine most frequently used to detect the antigen-specificity of 
specific CD8+ T-cells. Inter-leukin-2, another cytokine which is also secreted by CTL T-
lymphocytes, is secreted at a much lower frequency compared to the secretion of IFN-g (Letsch 
and Scheibenbogen, 2003).  
 
Comprehensive screening ELISPOT assays detecting IFN-g secretion have been used to evaluate 
the magnitude, breadth and specificity of HIV-specific responses in several cohorts of HIV-
infected individuals (Currier et al, 2002; Addo et al, 2003; Feeney et al, 2003a; Kiepiela et al, 
2004 and Novitsky et al, 2002).  
 
Comprehensive screening using pooled peptides (arranged in a matrix format) which spanned the 
entire HIV-1 proteome was followed by confirmation of individual overlapping peptides (OLPs), 
if a positive pool was detected. The optimal peptides are shorter in length (shorter in amino acid) 
as compared to the OLP length and found within the sequence of the OLP. The optimal peptides 
were tested based on the individual’s HLA type (Appendix 18). 
 
Figure 18 shows the percentage frequencies of the HIV proteins targeted by twenty two of the 
























Figure 18.  The percentage frequencies of the individual proteins targeted within the 
HIV-1 proteome prior to starting treatment in 22 chronically HIV-1 infected children.  
 
 
In this cohort, the Pol HIV-1 protein was most frequently targeted (30%) followed by the total 
Gag HIV-1 protein (24%), Env HIV-1 protein (14%), Nef HIV-1 protein (12%), Rev HIV-1 
protein (8%), Vif and Vpr HIV-1 proteins (4%) each and the least or not targeted HIV-1 
proteins were from Tat and Vpu with 2% and 0% respectively. 
 
The Pol and Gag HIV-1 proteins were most frequently targeted in this chronic HIV-infected 
paediatric cohort. Hence the frequencies of the individual subunits indicated that the p24 
region was the most dominant subunit of the Gag HIV-1 protein (18%) as compared to the 
p15 and p17 regions which were less frequently targeted (2%) and (4%) respectively. The Pol 




Fifteen of twenty two (68.2%) children screened at baseline (prior to antiretroviral therapy), 
responded to at least one peptide in the p24 Gag region. The Gag p24 was the most frequently 
recognized subunit in the protein. Three children (13.6%) responded to the Gag (p17) subunit 
and only one (0.5%) child responded to the Gag (p15) subunit.  
 
Figure 19a highlights the number of children who responded to the overlapping peptides 
(OLPs) in the Gag (p15), Gag (p17) and Gag (p24) subunits. OLP #41 
(YVDRFFKTLRAEQATQDV) dominated the detectable responses by six children. OLP #41 
has been associated with T-helper responses (Ramduth et al, 2009). These 6 children also had 
a positive CD4+ T-cell response when tested with the pool of Gag peptides by the Intracellular 
Cytokine Staining (ICS) assay. Four children responded to OLP #22 
(WVKVIEEKAFSPEVIPMF) and #40 (GPKEPFRDYVDRFFKTLR). 
 
Figure 19b shows that only 6 peptides were targeted within the HIV-1 Env protein. OLPs 
#293 (VMGNLWVTVYYGVPVWK) and #325 (IRSENLTNNAKTIIVHL) are from the Env 
gp120 subunit.  OLP #362 (IVQQQSNLLRAIEAQQHM), #394 
(QRGWEALKYLGSLVQYWGL), #395 (LGSLVQYGWLELKKSAVSLL) and #396 
(ELKKSAVSLLDTIAIAVA) are from the gp41 subunit of the Env protein.  
 
In figure 19c, OLP #281 (ELKQEAVRHPFRPWLHGL) and #283 
(GLGQYIYETYGDTWTGV) were targeted from the Vpr protein and OLP #411 
(LQTGERDWHLGHGVSIEW) and #412 (HLGHGVSIEWRLRRY) were targeted from the 
Vif protein. These accessory proteins were less frequently targeted in this HIV-1 chronically 
infected cohort. Overall 15 peptides were targeted within the HIV-1 Pol protein as shown in 
figure 19d. 
 
Eleven OLP were targeted within the regulatory HIV-1 proteins. Six children targeted OLP# 
84 (NYTPGPGVRYPLTFGWCF) from the Nef protein as seen in figure 19e. The Rev and 
Tat peptides were less frequently targeted. 
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Figure 19.  The number of children who responded to overlapping peptides in the HIV-1 
genome: a) Gag (p15), Gag (p17) and Gag (p24) protein. b) Env (gp120) and Env (gp41) 





HIV-specific CD4+ and CD8+ T-cells  play an important role in the control of HIV-1 infection. 
Studies have failed to show a correlation between the magnitude and breadth of HIV-specific 
IFN-γ CTL responses with viral load (Addo et al, 2003, Buseyne et al, 2005; Ogg et al, 1998 
and Lacabratz-Porret et al, 2003). Figures 20a & 20b depict the 22 children that were screened 
for CTL responses and HIV-1 RNA plasma viral load before starting antiretroviral treatment. 
Figure 20a shows that there was no significant correlation between the magnitude of CTL 
immune response and the HIV-1 RNA plasma viral load. The Pearson’s correlation test 
calculated the r2 = 0.02805 and p = 0.4563. Figure 20b shows that there was no significant 
correlation between the number of OLPs targeted from all the HIV-1 proteins and the HIV-1 

































Figure 20: a) Shows the magnitude and b) the breadth of the CTL Immune responses for 
the twenty two chronically HIV-1 infected children screened before starting 
antiretroviral therapy. These results are consistent with those from other studies 
(Lacabaratz-Porret et al, 2003 and Plana et al, 2004) which also found no significant 
correlation between viral load and the total magnitude of HIV-1 specific responses 
before starting HAART. 
 
 
3.2.2 T-cell immune responses in the continuous treatment group  
 
Fifteen children were randomized to the continuous treatment arm of the study. The CTL 
HIV-specific immune responses waned and disappeared in only one child (6.7%) (PARV 09) 
whose viral load level reached undetectable limits during HAART. The optimal immune 
response was detected at 24 weeks on HAART and disappeared thereafter. The HLA type for 
PARV 09 was A4301/6802 B15/15 Cw03/1801. Although the B-alleles were typed and 
reported as two digits alleles, the responses suggest that B1503 and B1510 were the optimal 
B-alleles. 
 
Figures 21a and 21b indicate the overlapping peptides and optimal peptides respectively to 
which PARV 09 responded before starting HAART (0 weeks) and when treatment 
commenced. The yellow block indicates commencement and duration of treatment. A 
(20a) (20b) P = 0.4563 
r2 = 0.02805 
 
P = 0.4916 
r2 = 0.02395 
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response to the sequence of OLP #41 Gag (p24) and the sequence of OLP #100 (Rev) was 
made before starting HAART as well as at 12 weeks while on treatment. There were no 
detectable responses at the subsequent visits.  
 
The optimal epitopes B1510-IL9 in Rev, Cw03-YL9 in Gag (p24) and Cw18-ER15 in Gag 
(p24) were detected at 12 and 24 weeks on HAART and then disappeared. Optimal epitopes 
B1503-FY10 in Tat, B1503-VI10 in Pol (Int) and B1510-IL9 also in Pol (Int) were also 































     No responses
#100
















          



































Figure 21.  (a)  The OLP response increased marginally but disappeared over time on 
HAART. (b) The Optimal peptide response increased as well as new epitopes targeted 
but disappeared over time on HAART. The background indicates the treatment phase. 
 
PARV 13 had CTL responses and detectable viral loads from baseline until the 48 week 
follow-up visit. Due to treatment non-adherence, treatment in this child was stopped. 
Although this child was disenrolled after the 48 week follow-up visit, this child was clinically 







PARV 16 had no CTL HIV-specific immune responses before and during HAART, except for 
optimal immune responses Cw02-AY15-ULAACWWAGIQQEFGIPY (Pol-Int) and Cw18-
ER15-EDFRDYVDRFFKTLR (Gag p24) at the 12th week follow-up visit.   
 
 
Twelve of 15 children (80%) in the continuous treatment group of the study had CTL HIV-
specific immune responses before and during HAART. Seven of these 12 children (58.3%) 
had undetectable viral loads while the remaining 5 children (46.7%) had varying detectable 
viral load levels. Overall all 12 children in the continuous treatment group targeted almost all 
of the HIV proteins (Gag, Pol, Nef, Rev, Tat, Vif, Env and Vpr) during HAART with the 
exception of the Vpu HIV-1 protein. Table 4 depicts the 12 children who had varying CTL 
immune responses during HAART. Due to the insufficient number of PBMC’s, the ELISPOT 
assay was not performed at baseline (0 weeks) for PARV 02, PARB 08, PARV 24 and PARV 
25. However, the first available immune responses were shown. The CTL immune responses 
are shown before and/or during HAART. Overall broadening of the CTL immune responses 







Table 4: CTL immune responses to HIV-1 proteins before and/or during HAART 
 
  Gag Pol Nef Env Rev Tat Vif Vpr Vpu 
 
PARV 02 
 8  weeks  + + + + +     




 0  weeks +  +     +  
96 weeks  + +     +  
 
PARV 08 
 2  weeks   +       
96 weeks + + +       
 
PARV 10 
 0  weeks + + +  +  +   
96 weeks + + + + +  +   
 
PARV 11 
 0  weeks  +        
96 weeks  +    + +   
 
PARV 12 
 0  weeks  + +     +  
96 weeks  + + +    +  
 
PARV 20 
 0  weeks +    +  +   
72 weeks + +    + +   
 
PARV 22 
 0  weeks  +        
96 weeks  +        
 
PARV 23 
 0  weeks +         
96 weeks +      +   
 
PARV 24 
 24 weeks  + +       
96 weeks          
 
PARV 25 
 12 weeks  +        
96 weeks + +    +    
 
PARV 27 
 0  weeks  + +       
96 weeks  + + +  +    
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3.2.3 T-cell immune responses in the treatment interruption group 
 
The rationale for structured treatment interruptions (STIs) is based on immune stimulation in 
the form of auto-vaccination as a result of re-exposure to HIV during the viral rebound. The 
hypothesis forming the basis of STI in patients with primary infection is that the preserved 
immunity could control the viral replication once the treatment had stopped. For patients with 
chronic infection, the treatment interruptions may allow the stimulation of T-helper and 
cytotoxic T-helper (CTL) response (Bongiovanni et al, 2006). The HIV-1 CD8+ T-cell 
responses can be detected in children, however they tend to be much weaker than that of 
adults (Chandwani et al, 2004).  
 
The CTL responses of the eight children who had treatment interruptions are demonstrated in 
Figure 22. Figures 22(a-d) show the responses of the children who had five treatment 
interruption cycles, figure 22(e & g) and figure 22(f & h) had two and four treatment 
interruption cycles respectively. As can be seen from figures 22(a-d, f) at certain STI cycles 
the ELISPOT could not be performed due to insufficiency of PBMC availability. The 
difference in the number of STI cycles was due to the criteria of undertaking an STI cycle 
with respect to undetectability of viral load for 3 months (12 weeks) in individual patients 
before commencement of an STI.    
 
Seven of these eight children (Figure 22 a-c & e-h) responded to the Gag protein as well as to 
Nef, Pol, Vpr and Env proteins within the HIV-1 proteome. Three of these seven children, 
(Figure 22a-c), on availability of PBMC’s responded only to the Gag protein. PARV 05 
(Figure 22a), the Gag response was detectable before starting HAART and although the assay 
was not performed for the first three treatment interruptions due to insufficient cells to 
perform the assay, the response was still clearly seen at the STI 4 (~3000 SFCs) and a weaker 
response at STI 5. PARV 18 (Figure 22c) reflected similar results. In this patient the Gag 
response was seen from the second STI as the assay was not performed prior to this timepoint 
due to insufficient cells to perform the assay. PARV 14 (Figure 22b) had no response before 
starting HAART and was not tested during the first and second treatment interruptions due to 
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insufficient cells however a response (~280 SFCs) was made at the STI 4. There was no 
response made during STI 5. 
 
PARV 03 (Figure 22d) was the only child who was randomized to the treatment interruption 
arm who did not make a response to the Gag protein. However a Nef and a very weak Pol 
response were made prior to starting HAART. Due to insufficient cells at STI 1 and STI 2, the 
assay was not performed. A weak Pol response was still evident at STI 3 with no responses at 
STI 4. At the STI 5, a weak Nef and a strong Pol (~ 3000 SFCs) were made. 
 
In three patients ELISPOTs were able to be set up at baseline and all STI time points eg. 
PARV 29 (Figure 22e), PARV 28 (figure 22g) and PARV 26 (figure 22h). A weak immune 
response targeting Gag and Pol proteins was detected prior to starting antiretroviral therapy 
and in addition to the subsequent STIs, a Nef response was made in PARV 09 (figure 22e). 
Stimulation of CTL response was clearly depicted at the last treatment interruption.  
 
PARV 19 (Figure 22f) had CTL responses to Gag, Pol and Nef at baseline, lost the Gag and 
Nef responses at STI 2, had no CTL responses at STI 3 while CTL responses to Gag, Nef and 
Pol re-appeared at STI 4 at a higher magnitude compared to the baseline CTL responses to the 
same three HIV proteins.  
 
PARV 28 (figure 22g) had three main responses i.e. Gag, Pol and Vpr at all time points with 
Gag being the highest magnitude. The Env response is lost at the STI 1 and Nef at the STI 2. 
 
The most consistent CTL responses in PARV 26 at all time points were Gag and Vpr with Nef 









































































































PARV 05  (2 years 1month)




























































































PARV 18  (2 years 6 months)















































































PARV 29  (8years)
















































































PARV28  (12 years)
PARV 26  (5 years)
 
Figure 22.  Demonstrates the protein responses in the eight children who had treatment 
interruptions. Fig. 22(a-d) shows the subjects who had five treatment interruption cycles, 




3.3 INTRACELLULAR CYTOKINE STAINING (ICS) 
 
 
The virus-specific CD8+ T-cell response in acute HIV-1 infection is low in magnitude and is 
directed against a limited number of epitopes (Dalod et al, 1999). However during chronic 
HIV-1 infection, a vigorous immune response, which is due to the broadening of antigen 
stimulation, occurs (Streeck et al, 2007).  
 
The quality and specificity of the initial CD8+ T-cell responses may be associated with control 
of the initial viral replication (Pantaleo et al, 2004). Several studies have shown that CD8+ T-
cell responses mainly targeted against HIV-1 Gag are associated with low viral loads (Streeck 
et al, 2007; Gray et al, 1999; Kiepiela et al, 2007). In this study, virus-specific immune 
responses were tested in twenty-two of twenty-nine chronically infected children using 
intracellular cytokine staining (ICS). Responses were tested against the HIV-1 Gag protein 
since Gag is the most conserved region within the HIV-1 genome and as it has previously 
been shown that immune responses against Gag are important in the control of viremia. 
 
3.3.1 IFN-γ ICS in children before starting HAART 
 
Although all 29 children were tested during the study period, only 7 children (24%) were 
tested prior to starting HAART (figure 23). This was due to the insufficient amount of 
PBMC’s obtained for the test as other tests were also undertaken in order of priority. Table 5 
shows the seven children in their respective randomized treatment group. Comparison of Gag 
specific T-cell responses using ELISPOT and the ICS assays revealed that in six of the seven 
children (85.7%) there was at least one response to an OLP in the Gag region using the 
ELISPOT assay and this corresponded to a positive CD8+ and CD4+ T-cell response by the 
ICS assay. Only one child did not make a response to a HIV-1 Gag OLP in the ELISPOT 
assay and this was in keeping with the negative response to the CD8+ and CD4+ T-cell on the 
ICS assay. Hence there was a correlation between the two assays as far as Gag specific CD8+ 




Table 5.   Comparison of ELISPOT and ICS T-cell responses in the seven children that 
had sufficient PBMC’s for ICS testing before starting HAART. The ELISPOT Gag 




Gag #OLP Response:  
ELISPOT 
Gag pool CD8+ 
Response: 
ICS 






































































Figure 23. A schematic representation of the Intracellular Cytokine Staining and comparison to the ELISPOT tests in twenty-
nine children. 
N=29 
7 children tested at 
baseline 
22 children not tested at baseline 
16 tested 12 weeks on 
antiretroviral therapy 
6 children tested at alternate timepoints 
 (all had ICS Gag responses) 
9 children had ICS Gag 
response 7 children had no ICS Gag 
response 
8 had ELISPOT  
Gag response 
1 had no ELISPOT  
Gag response 
6 children had no 
ELISPOT  
Gag response 
1 child had ELISPOT 
Gag optimal response 
1 child had Gag 
OLP response on 
ELISPOT at other 
timepoints - not at 
the corresponding 
timepoint of the 
ICS assay 
3 children had 
ELISPOT Gag 
response at the 
corresponding 
timepoint 




not at the 
corresponding 
timepoint of 
the ICS assay 
6 children had 
ELISPOT Gag 
responses 
1 child had no 
Gag response on 
ELISPOT or ICS 
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3.3.2 CD8+ IFN-γ ELISPOT and ICS  
 
PBMCs from twenty-two children were tested by intracellular cytokine staining (ICS) during 
the study (figure 23). Sixteen of 22 (72.7%) children were tested at the 12 weeks timepoint 
(on treatment) whilst the remaining six children were tested at random timepoints whenever 
PBMC’s were available. 
 
Nine of sixteen children (56.2%) tested at 12 weeks, had a positive CD8+ and CD4+ T-cell 
response for the ICS assay, while 8/9 children had a gag response on the ELISPOT assay. A 
possible reason for the one child not having a gag response on the ELISPOT assay could be 
due to the low magnitude of the ELISPOT response (below the cut off point of detection as 
the limit of the assay). We have previously found that ELISPOT responses > 500 SFC’s will 
be detectable by ICS (Ramduth et al, 2005).  
 
In the rest of the seven of 16 children at the 12 weeks timepoint there was a correlation 
between the two assays whereby no Gag specific responses were detected in 6/7 children 
while in the remaining one child (PARV 06) there was a Gag specific response to optimal 
peptides A02-SL9-SLYNTVATL and B44-SL9-SEGATPQDL with a negative ICS response.  
 
All six children tested at alternate timepoints during the study had a positive Gag response for 
the ICS assay, while only three of the children had Gag specific ELISPOT response at the 
corresponding timepoint. The other three children did not have both assays done 
simultaneously due to insufficient PBMC’s despite making Gag specific responses by one of 
the assays. Hence the responses obtained cannot be compared. 
 
A comparison of the ICS (Gag pool of peptides) between the pre-HAART and the 48 weeks 
on antiretroviral therapy samples was undertaken (Figure 24). As can been seen in Figure 24, 
there was no difference in Gag-specific CD8+ T-cell response before or 48 weeks after 
antiretroviral treatment was started. Likewise, no difference in CD4+ T-cell Gag-specific 
responses was seen before or 48 weeks after antiretroviral treatment was started. 
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3.3.3 Comparison of CD8+ IFN-γ ICS before starting HAART to 48 






































Figure 24. CD8+ and CD4+ T-cell responses in seven children  who were tested at 
baseline (before starting HAART) and at 48 weeks on HAART.  
 
 
The median %IFN-g response at baseline was (1.15%) and (0.09) for the CD8+ and CD4+ T-
cell respectively. The median % IFN-g response at 48 weeks was (1.09%) and (0.08) for the 
CD8+ and CD4+ T-cell respectively. The benefits of HAART have been clearly documented in 
several clinical studies. Despite the control of viral replication and increases in the CD4+ T-
cells, HAART does not eradicate the virus and it does not reconstitute the HIV-specific 







Intracellular cytokine staining (ICS) of PBMCs was undertaken at different timepoints, on one 
of the children (PARV 09) who was randomized to the continuous treatment group of the 
study. IFN-g production by Gag specific CD8+ T-cells, at the pre-HAART timepoint was 
0.23% (figure 25c); 0.075% at 52 weeks (Figure 26c) and 0.13% at 72 weeks of antiretroviral 
treatment (Figure 27d). IFN-g production by Gag specific CD4+ T-cells, at the pre-HAART 
timepoint was 0.085% (figure 25f); 0.06% at 52 weeks (figure 26f) and 0.068% at 72 weeks of 
antiretroviral treatment (figure 27j). 
 
The decrease in the production levels of IFN-g Gag-specific CD8+ T-cells was evident after 
the initiation of HAART in this child, as the viral load decreased to levels below the detection 
limits. However, there was little difference in Gag-specific CD4+ T-cell responses before or 
during antiretroviral treatment 
 
HIV-specific CD4+ T-cell response has shown to be absent or severely impaired in the 
majority of HIV-1 chronic infections (Shedlock et al, 2003). This generally leads to the 









































































































































Figure 25. ICS for Parv 09 at baseline (pre-HAART) 
(a) (b) (c) 




PARV 9-52 WKS -VE
Event Count: 54176
100 101 102 103 104
















                 
FL3-H, FL4-H subset
PARV 9-52 WKS +VE
Event Count: 34007
100 101 102 103 104
















                     
FL3-H, FL4-H subset
PARV 9-52 WKS GAG
Event Count: 54687
100 101 102 103 104



















PARV 9-52 WKS -VE
Event Count: 54176
100 101 102 103 104
















          
FL3-H, FL4-H subset
PARV 9-52 WKS +VE
Event Count: 34007
100 101 102 103 104
















                
FL3-H, FL4-H subset
PARV 9-52 WKS GAG
Event Count: 54687
100 101 102 103 104


















Figure 26. ICS for Parv 09 at 52 weeks on treatment 
   (a) (b) (c) 


















































































































































































Figure 27.  ICS for Parv 09 at 72 weeks of treatment 
(a) (b) (c) (d) 
(e) (f) (g) (j) 
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3.4 HIV-1 DRUG MUTATIONS AND RESISTANCE 
 
Cytotoxic T-lymphocyte cell (CTL) responses develop and persist during HIV-1 infection in 
therapy naïve subjects. The virus however evades immune surveillance and this is due to CTL 
escape mutations (Allen et al, 2000; Goulder et al, 2001). Resistance to antiretroviral drugs in 
previously untreated HIV-infected people is a growing problem with public health 
implications (Oette et al, 2004). Transmitted or acquired resistance prior to a combination of 
HAART may compromise the effectiveness of nevirapine (NVP) or other NNRTI based 
HAART regimes in particular when NVP is provided for the prevention of mother-to-child 
transmission (MTCT). HIV-1 drug resistant mutations detected during structured treatment 
interruptions have generally been selected by agents with relatively prolonged intracellular 
half-lives and for which a single-base pair change in HIV-1 confers high-level drug resistance 
(Oette et al, 2004). 
 
 
3.4.1 Drug Resistant Mutations before starting HAART 
  
Thirty children (fig 7) were treated with a combination of three nucleoside reverse 
transcriptase inhibitors (NRTI). These were AZT, ABC and 3TC. Resistance testing was 
performed on frozen plasma samples for all children prior to starting antiretroviral treatment. 
Drug mutations to NRTIs and NNRTIs were tested. Three children (PARV 03, PARV 05 and 
PARV 18) were reported to have had single-dose Nevirapine (NVP) at birth. Twenty-six of 
thirty children had no drug resistance mutations before starting HAART. Table 6 indicates the 
four of thirty children who had at least one resistant mutation to NRTIs and/or NNRTIs prior 
to starting HAART. There was no significant difference with regards to viral loads with the 
four children who had pre-HAART drug mutations as compared to the other 26 children who 
did not have a pre-HAART drug resistant mutation. PARV 02 and PARV 18 had one NRTI 
resistant mutation each and PARV 04, PARV 14 and PARV 18 had one NNRTI mutation 
each. It is possible that these children were infected with this resistant strain of HIV-1. PARV 
18 received a single dose NVP at birth and it is likely that this children developed resistance to 
the NVP as the mutation was detected at all time points tested and not after initiating HAART. 
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Table 6.     Drug resistance mutations in four children prior to starting HAART  
 
  DRUG MUTATIONS 
No. Sample ID NRTI NNRTI 
1 PARV 02 a M41L None 
2 PARV 04 b None G190EG 
3 PARV 14 b  None V179D 
4 PARV 18 b T69N Y181C 
  a randomized to the continuous treatment group    




Only one child (PARV 02) had a baseline drug mutation (M41L) to the NRTI regime. Once 
antiretroviral treatment commenced, the viral load was undetectable up until the last visit at 96 
weeks. It was reported that this child had defaulted with the treatment program hence allowed 
for a viral rebound to occur. A confirmation test was done a month later after the child had 
restarted antiretroviral treatment. The viral load decreased significantly (data is not shown). 
 
 
Four of fifteen children (PARV 11, PARV 12, PARV 16 and PARV 20), who were 
randomized to the continuous treatment group, developed drug mutations after starting the 
triple NRTI combination. Interestingly these 4 children were not the same that had the pre-
HAART drug resistant mutations. Although the viral loads decreased for each child, it did not 
reach undetectable levels. The M184V drug mutation (to the 3TC ARV drug) was the only 
mutation that was evident in all of these four children. 
 
Three of the fifteen children randomized to the treatment interruption group, had a drug 
mutation prior to starting HAART (table 6).  The viral load for PARV 04 had reached 
undetectable levels at 12 weeks (on treatment) but thereafter continued to increase despite the 
ARV treatment. Due to detectable viral load levels at 24 weeks, this child did not have a 
treatment interruption, hence continued with the treatment program. Although PARV 14 and 
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PARV 18 had drug mutations prior to starting HAART, the viral loads were undetectable at 
24 weeks, hence they had five and four treatment interruptions respectively. PARV 14 
developed resistance to 3TC and the drug mutation M184V was detected after the first 
treatment interruption. Although the viral loads were undetectable, the M184V and V179D 
mutations were evident at successive timepoints (26, 33, 52, 62 and 77 weeks). PARV 18 had 
two drug mutations prior to starting HAART. However, this did not affect the four treatment 
interruptions this child had due to the undetectable viral loads. The mutations were present at 




3.4.2 Drug Resistant Mutations after initiating HAART 
PARV 13 was forced to stop the treatment program. Due to social-economic problems, this 
child was non-adherent to the ARV treatment. This however would have resulted in serious 
implications of developing drug resistance. PARV 13 was monitored by the clinician and 
social-welfare. 
 
Fourteen of the twenty nine children (48.3%) who were monitored longitudinally, developed 
drug resistant mutations. Interestingly as table 7 indicates, 4/14 children (28.6%) developed 
drug resistant mutations whilst their viral loads were undetectable and they also underwent 
treatment interruptions. 
 
Three of 4 children (75%) developed only the M184V drug resistant mutation. Treatment 
interruption did not have an affect on the acquisition of this mutation as PARV 12 and PARV 
15 had continuous treatment and still acquired the M184V mutation. The D67N, K70R as well 
as the M184V drug resistant mutations were common in seven children (PARV 06, PARV 11, 












PATIENT  ID 
 
NRTI  MUTATIONS 
 








2 PARV 04 M184V G190EG 
3 PARV 05 C M184V, K65R  
4 PARV 06 M184V, M41L, D67N, K70R, 
T215Y, K219EKQ 
 
5 PARV 11 M184V, D67N, K70R  
6 PARV 12 M184V  
7 PARV 14 C M184V V179D 
8 PARV 15 M184V  
9 PARV 16 M184V, D67N, K70R,  
Y115FY, T215IT, K219EQ,  
G333E 
 
10 PARV 17 M184V, D67N, K70R, K219N  
11 PARV 20 M184V, D67N, K70R,  
T215IV, K219Q 
 
12 PARV 21 M184V, D67N, K70R  
13 PARV 29 C M184V  
14 PARV 30 M184V, D67N, K70R  
    
C  Had treatment interruptions 
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3.4.3 3TC Drug Resistance Mutation 
The M184V mutation confers high-level resistance to 3TC and this was the most dominant 
mutation in this cohort. Although this mutation is associated with a significant reduction in the 
HIV’s ability to replicate, it has been hypothesized that continuation of 3TC despite 
documented resistance, could provide an overall benefit (Castagna et al, 2006). Resistance to 
3TC is associated with the substitution of isoleucine for methionine at position 184 of HIV-1 
RT region, which results in a single base pair change (ATG–ATA). The M184I variant is 
rapidly replaced by the variant M184V during 3TC therapy (Sarafiano et al, 1999). 
 
Fourteen of the thirty children (46.7%) enrolled in this study developed the M184V mutation 
(10 children received continuous treatment while 4 children had treatment interruptions). 
There was no difference in the response to the treatment in the 14 children who developed the 
M184V mutation during their treatment as compared to those children who did not develop 
the M184V mutation. This mutation was not present in any of the thirty children before 
starting HAART as resistance testing was performed on pre-HAART samples (table 7).  
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The Human Immunodeficiency Virus (HIV) has long been demonstrated to be the causative 
agent of AIDS. Despite the tremendous advances in the research field such as the development 
of life-extending antiretroviral drugs and understanding the cause and course of the disease, 
HIV continues to wreak havoc on a global scale especially in resource-poor countries where 
devastating consequences are seen. Without an effective prophylactic and therapeutic HIV-1 
vaccine, which is cost-effective, HIV-1 will remain a global public health catastrophe. 
 
The long-term use of HAART is expensive and difficult for many patients (especially infants 
and children) to follow and manage. Drug toxicity is generated as a result of constant drug 
intake (Lisziewicz et al, 2002). Therefore the implementation of Structured Treatment 
Interruptions (STI) was initially thought to be a promising intervention for the treatment of 
HIV-1 infection, which offered a cheap and less toxic alternative to continuous antiretroviral 
therapy. Previous studies that involved STIs in chronic HIV-1 infection focused mainly on 
adult subjects. Results obtained in January 2006, evaluated by the Data Safety and Monitoring 
Board (DSMB) from one of the largest STI studies in the world, The Strategies for the 
Management of Antiretroviral Therapy (SMART Trial), suggested that there was an increase 
in major complications such as cardiovascular diseases, kidney and liver diseases as well as 
reported cases of deaths as a result of structured treatment interruptions. The DSMB thereby 
recommended that the SMART Trial be stopped and that all participants resume continuous 
therapy. Based on these findings, this pilot study stopped all further treatment interruptions 
 
The mean age of the participants in the SMART Trial was 46 years. In contrast the average 
age of the children in the current study was 5 years old. Studies of this nature have been 
limited in children. Therefore this randomized, controlled pilot study was performed to assess 
the use of STIs in chronically HIV-1 infected children in KwaZulu Natal, South Africa. This 
pilot study did not complete the full assessment of the use of STIs in this cohort and this was 
due to the outcome of the findings in the SMART study as mentioned above. All the children 
who were randomized to the STI arm of the study and had treatment interruptions, resumed 
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continuous therapy and the children were then followed-up on their routine scheduled visits 
until the end of the study period. 
 
Although investigators indicated that the clinical outcomes in the drug conservation arm 
(structured interruption arm) of the SMART study were inferior, the factors that contributed to 
such adverse findings in this major trial is still being investigated. However, a major 
difference between the SMART Trial and this pilot study is the fact that there were no deaths 
reported in this cohort and the quality of life in these children has improved significantly. 
However, it should be noted that clinical and laboratory monitoring in the SMART trial was 
much more stringent and this could account for the differences between the two studies. 
 
The results in this study showed good clinical response to HAART in the majority of the 
children. An exception to this was the side effect of one of the antiretroviral regimes, Abacavir 
which causes “hypersensitivity” and has been reported to cause severe illness and/or death. 
Previous studies have demonstrated that the HLA-B*5701 allele, which is most common in 
Caucasian populations, has a high predictive value for this reaction (Mallal et al, 2002).  
 
 PARV 01, a five-year old male child, was enrolled to this pilot study, experienced this 
“hypersensitivity” to Abacavir within the first week of starting the triple nucleoside 
combination. HAART was immediately suspended in this child and although the CD4 
percentage of this child remained above the National Roll-Out cut-off value, he was still 
managed clinically by the study clinician but was not part of the pilot study analysis. 
Interestingly, this child did not possess the HLA-B*5701 allele.  
 
There is now significant research evidence to indicate which antiretroviral drug combinations 
are best in terms of reducing ill health and extending survival. The anti-drug classes include: 
nucleoside analogues, non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease 
inhibitors (PI) (Appendix 15).  
 
In South Africa the first and second line antiretroviral-drug regime currently includes two 
nucleoside analogues and one NNRTI. This study however, used a recommended alternative 
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regime that consisted of three nucleoside analogues (i.e. AZT, 3TC and Abacavir). This was 
because the study design had been decided upon at least 3-4 years before the South African 
Government Roll-Out ARV Programme. At that time this was the best possible regime for 
children. However, due to lack of funding this pilot study was only commenced in January 
2004. 
 
A triple nucleoside combination is usually considered to be administered to HIV-infected 
individuals if they have a low viral load or if there are concerns regarding treatment 
adherence. However the major advantage of a triple nucleoside regime is that they are simple, 
more tolerable, involves fewer pills and causes fewer problems with drug interactions and side 
effects. 
 
Patients on antiretroviral therapy demonstrate a decrease in viral load levels often to 
undetectable levels while improving their immune system with a CD4+ T-cell count rise. It is 
not uncommon for patients to have increasing viral loads while on treatment with a steady 
increase in CD4+ cell count. The discordance between T-cell counts and viral load is often 
referred to as the Disconnect Syndrome (Berger, 2002). This is an observation of the 
difference between the viral and immunological laboratory measures which includes the viral 
load and the CD4 cell counts. 
 
Disappointing news in 2003 regarding this triple nucleoside regime only got worse in 2004 by 
which time this pilot study had already began. This disappointment began with preliminary 
data with the triple nucleoside regime in the AIDS Clinical Trials Group (ACTG) 5095 Study, 
where a high rate of early virologic failure and rapid development of resistance was evident 
(Gulick et al, 2004). As a result of this ACTG 5095 Study, the Department of Health and 
Human Services (DHHS) guidelines did not recommend the triple nucleoside reverse-
transcriptase combination of AZT/3TC/ABC, unless no other treatment options are available. 
 
Overall this study showed that the CD4 percentages increased markedly during the first 12 
weeks (3 months) of starting antiretroviral therapy. These results are in keeping with the data 
obtained from the retrospective studies with HIV-infected children in Mombasa, Kenya (Song 
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et al, 2007) and in Thailand (Puthanakit et al, 2005). A report from West Kenya that followed 
up on children from 9 different clinics, indicated that there was a significant increase in the 
CD4 percentages after treatment was initiated with the greatest increase noted during the first 
30 weeks. 
 
The current study of STIs in chronic HIV-1 infected children showed that in the 8 children 
who had treatment interruptions, 50% (4/8) of the children had viral rebounds to their pre-
HAART baseline levels during the treatment interruptions and small changes (decrease in 
number) were noted in the CD4 percentages during the treatment interruptions. As shown in 
figure 15 (a & b), the overall CD4 counts and viral load measurements at the end of the 2 year 
follow-up period were consistent with good outcomes. There were no differences with regards 
to the outcomes of the CD4 counts and viral load measurements in the continuous treatment 
group and treatment interruption group. These results are consistent with previous studies 
(Ruiz et al, 2000; Papasavvas et al, 2000; Hatano et al, 2000 and Ortiz et al, 2001). 
 
Safety was a primary concern when treatment interruptions were performed in this study. The 
study protocol mandated the first treatment interruption after 24 weeks (6 months) of the triple 
antiretroviral regime, only if the viral load was undetectable (i.e. <400 HIV-RNA copies/ml). 
Treatment resumed if there the viral load increased to ≥1000 HIV-RNA copies/ml. 
 
In almost all of the treatment interruption studies performed, treatment interruption cycles 
were standardized for the participants within the cohort. The Swiss-Spanish study used 4 
HAART cycles of 2 weeks “off” HAART and 8 weeks “on” HAART. Other studies used 7 
days “on” HAART followed by 7 days “off” HAART (Dybul et al, 2001) while another study 
used 1-month “off” HAART followed by 1-month “on” HAART (Ortiz et al, 2001). This 
study focused on the individual child and therefore the length of the treatment interruption 
was variable. The study protocol to resume therapy was guided by the viral load criteria of 
≥1000 HIV-RNA copies/ml and not the CD4+ T-cell percentage as described in other studies 
(Thobakgale et al, 2007; Chakraborty et al, 2003). Some studies used the viral load as the 
treatment resumption criteria. In these studies, treatment resumed if the viral load was >100, 
000 copies/ml (Ortiz et al, 2001 and Molto et al, 2004).  It was not established whether the 
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outcome of this study would be any different, if the criteria for resuming HAART after a 
treatment interruption was changed, firstly to increase the viral load cut-off to 100, 000 HIV-
RNA copies/ml (log 5.00) or secondly to include the CD4 percentages, like in the above 
mentioned studies.  
 
In this study no death or major opportunistic infections were observed during the course of 
treatment. STIs may be able to reconstitute the immune system in some chronic infected 
individuals, but this outcome is both variable and difficult to predict. The quality of the 
immune reconstitution during chronic infection appears to be different from acute infection. 
The immune control of HIV replication during treatment interruption in acute HIV-1 infection 
is better achieved than in chronic HIV-1 infection, where the HIV rebounds are usually higher 
(Altfeld et al, 2001). 
 
The screening of the overlapping HIV-1 peptides in an IFN-gamma ELISPOT assay at 
baseline revealed that the majority of these perinatally chronic HIV-1 infected children 
mounted HIV-1 specific CD8+ T-cell responses that were weak and narrowly directed to a 
limited number of epitopes. These findings are consistent with prior studies which included 
perinatally HIV-1 infected children (Luzuriaga et al, 1995; Luzuriaga et al, 2000; Scott et al, 
2001; Spiegel et al, 1999 and Spiegel et al, 2000). However, these findings, contrast with the 
data obtained in a study (Feeney et al, 2003a) where young perinatally HIV-1 infected 
children mounted broad and vigorous CTL responses which targeted multiple epitopes within 
the HIV proteome. There was a significant difference with regards to the age of the children in 
the above mentioned study as compared to the PARV study. The average age of the children 
in above mentioned study (Feeney et al, 2003a) was 10 years with a range of 6-17 years. In 
the PARV study the average of the children was 5 years with a range of 2-12 years. With 
regards to HAART, 16 children were on HAART and only 2 children were treatment naïve 
(Feeney et al, 2003a). The possible reasons for the differences of the CD8+ T-cell HIV-1 




In this study, all the children had detectable CD8+ T-cell responses directed towards the Gag 
and/or to at least one other protein of the virus before starting antiretroviral therapy. The Gag 
(p24) protein was the most frequently recognized subunit protein in this chronic HIV-1 
infected cohort (Figure 16). Preferential targeting of Gag by the CD8+ T-cells as compared to 
targeting other proteins within the viral genome is the fact that Gag may tolerate less sequence 
diversity because it is the most highly conserved protein in the HIV proteome (Ramduth et al, 
2005; Feeney et al, 2003a; Kaushik et al, 2005 and Streeck et al, 2007). 
 
Although the Gag p24 subunit of the protein was most frequently targeted in this study, the 
overall highest total contribution in the HIV-1 proteome was the Pol protein followed by Gag, 
Nef and Env proteins. Feeney et al, (2003b), showed the order of magnitude of the most 
frequently targeted proteins were Gag, Nef and Pol in perinatally HIV-1 infected children. 
Differences were observed in the relative contribution of each protein to the anti-HIV-specific 
CD8+ T-cell responses between acute and chronic therapy naïve children. The order of 
magnitude in a paediatric acute study was Nef protein followed by Gag and then Env proteins 
(Thobakgale et al, 2007). In contrast Fu et al, (2007), showed that Gag, Pol and the Nef were 
the most frequent targets in chronic adult HIV-1 infection. 
 
With the exception to the Vpu protein, which was not targeted by any of the children, the 
regulatory and accessory proteins were infrequently targeted. In particular, the early expressed 
proteins Tat and Rev were recognized by minority of the children in the cohort. These 
findings are consistent with data from other studies (Feeney et al, 2003b and Ching et al, 
2007). 
 
There was no correlation between the total sum of CD8+ T-cell responses and plasma viral 
load before starting antiretroviral therapy (Figure 18A and 18B). The IFN-γ ELISPOT assay 
does not permit the differentiation between CD8+ and CD4+ T-cell responses. Therefore the 
IFN-γ ICS assay which allows for the simultaneous quantification of both CD4+ and CD8+ T-
cell responses was performed.  
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Results from our laboratory indicate that the majority of the chronically HIV-1 clade C 
infected children, maintained HIV-specific CD8+ and CD4+ T-cells that produced IFN-gamma. 
Preferential targeting of Gag by the CD8+ and CD4+ T-cells were associated with control of 
viremia in these chronic HIV-infected children (Ramduth et al, 2005). 
 
Virus-specific CD4+ T-cell responses are important in maintaining effective immunity to a 
number of viral infections (Rosenberg et al, 1997) but are usually undetectable during the 
chronic phase of HIV-1 infection. The reason is probably because these CD4+ T-cells are 
preferentially targeted by HIV-1 (Douek et al, 2000). In this study, majority of the children 
(21/29) had a HIV-1 specific CD4+ T-cell response to the Gag pool of peptides in the 
intracellular cytokine staining assay while in twenty of these children there was also a Gag 
response on the ELISPOT assay. Although baseline (pre-HAART) ICS testing was performed 
in seven children, testing of the remaining twenty two children, at varying timepoints, 
indicated that IFN-γ CD4+ and CD8+ HIV-1 Gag-specific T-cell responses were still 
detectable despite being on HAART. Repopulating the T-helper lymphocytes after HAART 
involves naïve CD4+ T-cells in children (de la Rosa and Leal, 2003) with a small increase in 
memory CD4+ T-cells which reflects on the thymic capacity (Gibb et al, 2000). 
 
The effects of HAART on the virus specific CD4+ and CD8+ T-cell responses showed that the 
CD4+ and CD8+ T-cell responses waned over time on HAART, however in 3 children, the 
CD4+ and CD8+ T-cell responses disappeared whilst on HAART.  
 
Although the IFN-γ ICS data was limited to a small sample size and infrequent timepoints, a 
positive association between the HIV-1 specific CD4+ and CD8+ T-cell responses was seen. 
The magnitude of the CD8+ T-cell responses was higher than that of the CD4+ T-cell 
responses and this was also seen in other studies (Ramduth et al, 2005 and Lacabaratz et al, 
2003). The magnitude of these responses increased during the treatment interruptions and 
decreased during the treatment phase. 
 
The M184V mutation (associated with 3TC resistance) was a frequently (36%) selected 
mutation both in the continuous treatment group as well as in those children who had 
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treatment interruptions. 3TC is known to have a longer half-life in the cell and not necessarily 
in the blood. Although the M184V mutation was a frequently selected mutation, it was found 
only after repeated treatment interruptions in the treatment interruption arm of the study. 
Similar findings were obtained in the Swiss cohort (Yerly et al, 2003) with the median time on 
HAART being 27 months (range 9-45 months) as compared to this study which was a 24 
month study period.  
 
The V179D mutation associated with NVP resistance was identified in one child (PARV 14) 
prior to starting HAART and this mutation was maintained through the study period. The 
Y181C mutation associated with NVP resistance was evident in PARV 18 who was reported 
to have received a single-dose of NVP at birth. Drug resistant mutations are common 
especially in South Africa as single-dose NVP provides prophylaxis for the prevention-of-
mother-to-child-transmission (PMTCT) of HIV infection (Kurb et al, 2007).   
 
A study which looked at STIs in adult patients with multi-drug resistance HIV found that the 
STI was associated with greater progression of the disease and did not confer immunologic or 
virologic benefits or improve the overall quality of life (Pai et al, 2009). In comparison, all of 
the HIV-1 chronically infected children in this pilot study were reported to have improved 
quality of life. There were no reports of deaths. There was an increase in their CD4 
percentages and decrease in the number of HIV-RNA copies/ml. There were two children who 
had baseline drug resistant mutations who had treatment interruptions. Other studies have 
indicated that resistance in HIV-1 infection in infants is not only due to transmission of drug 
resistant virus but continued therapy is also associated with drug resistance (Noe et al, 2005). 
 
Although HAART significantly delays disease progression and prolongs life expectancy in 
children, viral suppression is often incomplete or transient in treated individuals and this was 
due to various factors such as host immune response impairment and viral resistance (Feeney 
et al, 2005).  In this study there were 6 children who maintained a detectable viral load 
throughout the study period of 24 months.  A further 7 children who reached an undetectable 
viral load during the study period (most of them by twelve weeks on HAART) had detectable 
viral loads thereafter.  
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The mortality rates of untreated HIV-infected children are extremely high, especially within 
the first 5 years of life (Nicoll et al, 1994, Spira et al, 1999, Taha et al, 2000). The majority of 
the children on this study survived past that age without HAART and this suggest that these 
children were paediatric slow progressors. 
 
This pilot study that focused on HIV-1 specific T-cell responses in chronic HIV-1 infected 
children during continuous treatment and treatment interruption periods had several 
limitations. Firstly as this was one of the first studies which focused on chronic HIV-1 
infection in children, the protocol used for the STI was not ideally suited. The STIs probably 
started too early after the initial treatment phase of the study before the children had a chance 
to stabilize and this was evident by the fact that 6/14 children in the treatment interruption 
group did not reach undetectable viral load levels by 24 weeks of treatment. Secondly this 
study used viral load monitoring to dictate treatment interruptions and the treatment 
interruption periods were very short for at least 5/8 children. This does indicate that this is not 
a true “structured treatment interruption.” Thirdly there was a variation in the age of children 
(2-12 years). Due to the small sample size of the study, it was difficult to distinguish age 
groups as older children may have stronger immune responses as compared to the younger 
children. Fourthly it was difficult to obtain adequate blood sample from all the children, and 
this made it impossible to do all assays at all time points. Lastly as I had no access to the 
WHO staging and other clinical data to categorically state that there were no differences 














The course of HIV-1 infection in infants and children is different to that in adults, and it 
is therefore important that monitoring, care and treatment of these HIV-1 infected infants 
and children be tailored and optimized accordingly. Children are not all the same, and 
there are obviously age-related differences which affect adherence. For children of school 
going age, adherence to regimes that require them to take doses at school can be difficult 
as it could lead to their HIV status being disclosed. Childhood infections such as measles 
and chickenpox can have very severe health implications for HIV-positive children and 
immediate medical advice should be sought if they have been exposed to or infected with 
these diseases.  
 
There were no statistically significant differences with regards to age, gender, pre-
HAART CD4 percentages and pre-HAART log viral loads, between the structured 
treatment interruption group and the continuous treatment group in this pilot study. 
Fourteen children (48.28% of the children) in this study had a ≥10% increase in their 
CD4 percentage by twelve weeks on HAART. 
  
Most HIV proteins were targeted by the CTLs in this chronic paediatric HIV-1 infected 
cohort. The Gag (p24) was the most dominant protein which was targeted by a majority 
of the children screened at baseline (pre-HAART). The Pol and Nef proteins were also 
frequently targeted. Both Gag-specific CD4+ and CD8+ T-cell responses were evident in 
the cohort. Gag specific CD8+ T-cell responses were of greater magnitude as compared to 
the Gag-specific CD4+ T-cell responses.  The presence of the HIV-1 specific CD4+ and 
CD8+ T-cell responses were evident with and without HAART. Although the pre-
HAART HIV-specific T-cell responses were narrow and weak, broadening of T-cell 
responses was evident in both treatment groups. The data in this pilot study indicates that 
structured treatment interruptions in this cohort were of a short duration due to the fast 
rebound of viral load upon interruption of HAART. 
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The M184V resistant mutation (3TC) was the most frequently detected mutation in this 
cohort. This M184V mutation was detected in children during treatment interruptions as 
well as in children who were randomized to the continuous treatment arm of the study. 
Despite having the M184V resistant mutation, viraemia was controlled and the CD4+ T-
cell percentages were stable. 
 
Antiretroviral therapy has been shown to be effective in older infants and children, many 
of whom are living longer and healthier lives. Although HAART has reduced HIV 
mortality significantly, prolonged treatment that suppresses the plasma viremia does not 
eradicate HIV and therefore, therapy must be continued throughout life in HIV-infected 
individuals. Overall there were no deaths in this cohort during the study period and all the 
children were reported to be clinically well at the end of the study. 
 
In this pilot study we used viral load monitoring to dictate treatment interruptions and 
found that the time off treatment was very short. The final outcome with regards to the 
CD4 and viral load, at the end of the 2 year follow up period, indicated that there was no 
difference between the continuous and treatment interruption groups. It is not possible to 
make any definitive statements on the use of treatment interruptions due to the small 
sample size, however, this study suggests that it is important to continue to explore 















1. Informed Consent Form  
 
INFORMATION GIVEN TO SUBJECTS 
Title of study: Assessment of Intermittent and Continuous Anti-retroviral Therapy 
regimens used for HIV-infected infants and children in Durban, South Africa 
 
You have been informed that your child is HIV positive and the doctor and nurse/ 
counsellor would have explained to you the importance of the test result and about 
HIV infection. We request your permission for your child to take part in a study. This 
study will look at giving children medicines to treat the HIV infection. The doctor will 
also explain the HIV infection and how the medicines may help your child. The 
medicines we plan to use have already been tested and shown to be effective in adults 
and children in other places in the world. We will give your child three types of 
medicines for 6 months. The doctor will explain the details of each of these medicines 
and how they should be taken. You will also be informed about the number of times 
your child has to come to the clinic and what blood tests need to be done.  
 
At the end of 6 months, we will do blood tests to see whether the medicines are 
helping your child.  If they are, your child will be entered into the second part of the 
study.  If the medicines are not helping, we will stop them, but continue to look after 
your child in our clinic. 
 
In the second part of the study, your child will take part in either one of two arms, 
which will occur by chance.  In one part of the study, all the children will continue to 
take the medicines in the same way as the first 6 months.  In the other part of the study, 
we will stop your child’s medicines when blood results show us that he/she is doing 
very well.  We then give the body a chance to “rest” from the medicines.  During this 
time, we will do more blood tests (to check on the virus and the body’s response to the 
infection), so you will need to attend the clinic regularly.  If at any stage, we are 
concerned about your child’s blood results, we will re-start the medicines.  Both 
systems of treatment will continue for 2 years. 
 
Any questions you have will be answered before you agree to allow your child to take 
part in the study. The study will last about 2 years and your child will also be offered 
ongoing free treatment with the same medicines, if the child is doing well on the 
medicines and you have been attending the clinic regularly, as requested by the 
doctors. 
Your child will visit the clinic about 12 times during the study. We will pay for any 
additional travelling expenses. We cannot guarantee that the treatment will work. You 
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will have to sign to indicate your agreement to take part in the study. You have the 
right to withdraw from the study at any time and this will not affect the treatment your 
child is entitled to.  We will continue seeing your child at the clinic. 
There are several things in the study that may cause inconvenience or discomfort. 
Firstly blood will be taken from your child regularly to check the state of the HIV tests 
and to look for side-effects of the medicines. There may be pain and bruising at the site 
of the injection. The study medicines may cause some side-effects such as a skin rash, 
fever and swelling of the glands. Your child will be seen by the doctor and carefully 
examined at each clinic visit. You may also bring the child to the clinic any time you 
notice any problem. 
G.6 INFORMED CONSENT FOR INCLUSION IN A STUDY (NOT TO BE USED 
FOR PHARMACEUTICAL STUDIES)  A TRANSLATION INTO THE HOME 
LANGUAGE OF THE SUBJECT MUST BE PROVIDED.  
Title of study: Assessment of Intermittent and Continuous Anti-retroviral Therapy 
regimens used for HIV-infected infants and children in Durban, South Africa  
   
 G.6.1     I,(Name) 
hereby consent to the following Procedure and/or Treatment being conducted on 
myself or the person indicated in G.6.4 below:  
G.6.2 I acknowledge that I have been informed by:  
(Name)  Prof R Bobat 
concerning the possible advantages and possible adverse effects which may result from 
the abovementioned procedure and/or treatment and of the ways in which it is different 
from the conventional procedure and/or treatment.  
I,(Name) 
hereby acknowledge that I understand and accept that this study involves research and 
the "Information to Patients" leaflet has been handed to me in connection with this 
study.  
G.6.3 I agree that the above procedure and/or treatment will be carried out and/or 
supervised by  
(Name)  Prof R Bobat  
 G.6.4 I acknowledge that I understand the contents of this form, including the 
information provided in the "Information to Patients" leaflet and as the 
PARENT  GUARDIAN  OTHER (specify)      
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freely consent to the above procedure and/or treatment being conducted on:  
(Name)  
G.6.5 I am aware that I may withdraw my consent at any time without prejudice to 
further care.  
Signed:       Date: 
Subject/Parent/Guardian  
Signed:       Date: 
Witness  
Signed:       Date: 
Informant  
Signed:       Date: 
Researcher  
For illiterate subjects:  
 
Date: 
Mark with a 'X'  
  
Independent witness:  
  
  Date: 
Details of independent witness:  
1. Title plus name:  
 Telephone number:  
 
For additional information with respect to ethical aspects of this study, contact the 




2. Working FACS Lysing Solution (1:10 Dilution) 
  50µl        10X FACS Lysing Solution (BD Biosciences, San Jose, USA) 
 450µl    Sterile distilled water  
  
Method:  50µl of the 10X FACS Lysing Solution was diluted in 450µl of sterile 
distilled water. 450µl of the working FACS Lysing Solution was used for each test. 
 
3. 70% Ethanol 
 (a) 70% Ethanol (Viral load Assay – for 12 tests) 
4.5ml  Sterile distilled water 
10.5ml  99.7% Ethanol (Merck, Gauteng, South Africa) 
 
Method: 4.5ml of Sterile distilled water was added to 10.5ml of 99.7% Ethanol. 1ml 
of the 70% was used for each test. 
   
 (b) 70% Ethanol (DNA Isolation) 
 3ml Sterile distilled water 
7ml  99.7% Ethanol   (Merck, Gauteng, South Africa) 
 
Method: 4.5ml of Sterile distilled water was added to 10.5ml of 99.7% Ethanol. 1ml 
of the 70% was used for each test.  
 
4. Red Blood Cell Lysis Buffer 
 7.7g NH4Cl         (Sigma-Aldrich Inc, St. Louis, USA) 
 0.84g NaHCO3       (Sigma-Aldrich Inc, St. Louis, USA) 
 1 L Sterile Distilled water 
 
Method:  7.7g NH4Cl and 0.84g NaHO3 was dissolved in sterile distilled water. The 




5. Phosphate Buffer Saline (PBS) 
1 Phosphate Buffered Saline (Dulbecco A) Tablet (Oxoid Limited, 
Hamshiper,England) 
 100 ml Sterile distilled water  
 
Method:  One Phosphate Buffered Saline (Dulbecco A) Tablet was dissolved in 100 
ml sterile distilled water. The pH of the PBS solution was adjusted to approximately 
7.2. The solution was autoclaved for 10 minutes at 1150C and stored at room 
temperature. 
 
6. Phosphate Buffer Saline (PBS) + Antibiotics 
 1L Phosphate Buffer Saline 
1% of 100X Penstrep/Fungizone (P/S/F) (Biowhittaker, Cambrex Bio Science, 
Walkersville, USA) 
 
Method:  10 ml of the already prepared PBS was removed and discarded. 10 ml of a 
1% Penstrep/Fungizone (P/S/F) solution was added to the remaining PBS. The 
solution was mixed well and stored at 40C. 
 
7. R10 Media 
500 ml RPMI (Biowhittaker, Cambrex Bio Science, Walkersville, USA) 
50 ml Fetal Calf Serum (FCS) (Delta Bioproducts, Johannesburg, South Africa) 
5 ml of 200mM L-glutamine (Biowhittaker, Cambrex Bio Science,   Walkersville, 
USA) 
5 ml of 100X Penstrep/Fungizone (P/S/F) (Biowhittaker, Cambrex Bio Science, 
Walkersville, USA) 
5 ml of 1M Hepes Buffer (Biowhittaker, Cambrex Bio Science, Walkersville, USA) 
 
Method:  65 ml of RPMI was removed from the original 500 ml quantity. 50 ml of 
heat inactivated and filtered FCS, 5ml of 200mM L-glutamine, 5ml of 100X 
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Penstrep/Fungizone (P/S/F) and 5ml of 1M Hepes Buffer was added. The media was 
mixed well and stored at 40C. 
 
8. 2% Virkon Solution  
200g of Virkon Powder (Antec International, Sudbury, Suffolk) 
10 L Water 
 
Method:   200g of Virkon Powder was dissolved in 10 L of water.  
 
9. Blocking Buffer  
1L Phosphate Buffer Saline 
10 ml Fetal Calf Serum (FCS) (Delta Bioproducts, Johannesburg, South Africa) 
 
Method:  10ml of PBS from the already prepared 1L bottle was removed and 
discarded. 10ml of heat inactivated, filtered FCS was added to the remaining PBS. The 
1% solution was mixed well and stored at 40C. 
 
10. BCIP (5-bromo-4-chloro-3-indoly/phosphate) 
0.015g BCIP (BioRad Laboratories, Hercules, CA) 
 1 ml DMF  (Merck, Wadeville, Gauteng, South Africa) 
 
Method:  0.015g of BCIP powder was dissolved in 1ml of DMF. The final 
concentration was 15mg/ml. The solution was mixed well and stored at 40C. 
 
11. NBT (Nitroblue Tetrazolium Chloride) 
0.03g  NBT  (BioRad Laboratories, Hercules, CA) 
 700 µl DMF (Merck, Wadeville, Gauteng, South Africa) 
300 µl Sterile distilled water 
 
Method:  0.03g of NBT powder was dissolved in 700 µl DMF and 300 µl of sterile 
distilled water was added. The solution was mixed well and stored at 40C. 
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12. 1M TRIS Buffer 
12.1g TRIS (BioRad Laboratories, Hercules, CA) 
1L Sterile distilled water 
 
Method:  12.1g of TRIS powder was dissolved in 1L of sterile distilled water with the 
use of a magnetic stirring bar. The pH was adjusted to 9.3 with concentrated Hydrogen 
Chloride (HCl). The solution was autoclaved for 10 minutes at 1150C and stored at 
room temperature. 
 
13. Working Hybridization Buffer 
213ml Di-ionised Water 
55ml  SSPE Concentrate (Dynal Biotech, Bromborough, UK) 
7ml SDS Concentrate (Dynal Biotech, Bromborough, UK) 
 
Method:  7ml of the SDS Concentrate (was heated to 500C prior to use) 
and 55ml of the SSPE Concentrate (was heated to 500C prior to use) was added to 
213ml of de-ionised water. The buffer was mixed well and heated to 500C to ensure 
that all the components were in solution. The buffer was stored at room temperature 
for 3 months. 
 
14. Ambient Wash Buffer  and Stringent Wash Buffer 
1228.5ml  Di-ionised Water 
65ml SSPE Concentrate (Dynal Biotech, Bromborough, UK) 
6.5ml  SDS Concentrate (Dynal Biotech, Bromborough, UK) 
 
Method:  6.5ml of the SDS Concentrate and 65ml of the SSPE Concentrate was added 
to 1228.5ml of de-ionised water. The buffer was mixed well and then divided into two 
separate containers. 275ml was used for the Stringent wash buffer and 1025ml was 




15. Working Conjugate Solution 
5.3ml  Ambient Wash Buff  
16µl Streptavidin-Horseradish Peroxidase Conjugate (Dynal Biotech, Bromborough, 
UK) 
 
Method:  A cocktail of 5.3ml ambient wash buffer and 16µl of Streptavidin-




16. Working Citrate Buffer 
570ml De-ionised Water 
30ml  Citrate Concentrate (Dynal Biotech, Bromborough, UK) 
 
Method:  30ml of Citrate Concentrate was added to 570ml of de-ionised water. The 
working citrate buffer was mixed well and stored at room temperature for 3 months. 
 
17.       Working Substrate  
4.4ml Substrate A (Dynal Biotech, Bromborough, UK) 
1.1ml Substrate B (Dynal Biotech, Bromborough, UK) 
 
Method:  A cocktail of 4.4ml of Substrate A and 1.1ml of Substrate B was prepared 










ID A1 A2 B1 B2 C1 C2 
PARV 001 02 74 1510 44 0202 03 
PARV 002 29 74 15 35 04 04 
PARV 003 0301 2301 1503 5802 0202 0602 
PARV 004 24 68 0702 1510 0304 08 
PARV 005 23 29 08 44 03 1403 
PARV 006 02 29 44 44 07 07 
PARV 007 23 29 14 4201 0802 1701 
PARV 008 02 30 45 58 06 16 
PARV 009 4301 6802 15 15 03 1801 
PARV 010 29 3001 4202 57/570301 07 1701 
PARV 011 0301 3001 1503 5802 0202 0602 
PARV 012 3001 6601 4202 5802 0602 1701 
PARV 013 02 29 1302 1401 0602 08 
PARV 014 03 03 4501 5802 0602 06 
PARV 015 2301 4301 1503 5802 0202 0602 
PARV 016 01 3402 1503 8101 0202 1801 
PARV 017 23 3203 1503 1503 0202 0202 
PARV 018 02 2301 1510 5801 07 1601 
PARV 019 23 66 1510 5802 0602 1601 
PARV 021 2301 6802 1510 44 3 3 
PARV 020 0202 4301 1503 5703 07 18 
PARV 021 2301 6802 1510 44 3 3 
PARV 022 6802 7408 14 41 0802 1701 
PARV 023 3001 3201 5703 5802 1801 0602 
PARV 024 02 2301 0801 1503 02 04 
PARV 025 3402 6802 1503 44 4 4 
PARV 026 2 33 1516 4201 1601 1701 
PARV 027 2301/24 3201 1503 1503 0202 03 
PARV 028 23 6802 0801 4201 03 1701 
PARV 029 23 23 0801 1503 0202 03 
PARV 030 03 23 0801 41 07 1701 
 
18.     Human Leukocyte Antigen Types  
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19.    Anti-HIV Drugs Names 
 
Anti-HIV drug class Common names Brand names 
Nucleoside analogues AZT, ziduvodine RetrovirTM 
DdI, didanosine VidexTM 
3TC, lamivudine EpivirTM 
D4T, stavudine ZeritTM 
Abacavir ZiagenTM 
 






PI (Protease inhibitors) Lopinavir/ritonavir KaletraTM 
Indinavir CrixivanTM 
Nelfinavir ViraceptTM 
Saquinavir (hard gel capsule) InviraseTM 
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